

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : <b>C12N 15/12, C12P 21/02 A61K 37/02</b>		A1	(11) International Publication Number: <b>WO 93/00432</b> (43) International Publication Date: <b>7 January 1993 (07.01.93)</b>
<p>(21) International Application Number: <b>PCT/US92/05374</b></p> <p>(22) International Filing Date: <b>25 June 1992 (25.06.92)</b></p> <p>(30) Priority data: 720,590                    25 June 1991 (25.06.91)                    US</p> <p>(71) Applicant (<i>for all designated States except US</i>): GENETICS INSTITUTE, INC. [US/US]; 87 CambridgePark Drive, Cambridge, MA 02140 (US).</p> <p>(72) Inventors; and            (75) Inventors/Applicants (<i>for US only</i>) : WOZNEY, John, M. [US/US]; 59 Old Bolton Road, Hudson, MA 01749 (US). CELESTE, Anthony, J. [US/US]; 86 Parkard Street, Hudson, MA 01749 (US).</p>		<p>(74) Agent: KAPINOS, Ellen, J.; Genetics Institute, Inc., 87 CambridgePark Drive, Cambridge, MA 02140 (US).</p> <p>(81) Designated States: AU, CA, JP, KR, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE).</p> <p>Published <i>With international search report.</i></p>	
<p><b>(54) Title: BMP-9 COMPOSITIONS</b></p> <p>TGA ACA AGA GAG TCC TCA AGA ACC TGT CCA AGG AGC GCT CCA CAG AGG                    48 * Thr Arg Glu Cys Ser Arg Ser Cys Pro Arg Thr Ala Pro Gln Arg -41 -40                    -35                    -30</p> <p>CAG GTG AGA GCA GTC AGC AGG AGG ACA CGG ATG GCG CAC GTG GCT GCG                    96 Gln Val Arg Ala Val Thr Arg Arg Thr Arg Met Ala His Val Ala Ala -25                    -20                    -15                    -10</p> <p>GCG TCG ACT TTA GCC AGG CGG AAA AAG AGC GGC CGG GCT GCG AGC CAC                    144 Gly Ser Thr Leu Ala Arg Arg Lys Arg Ser Ala Gly Ala Gly Ser His -5                    1                    5</p> <p>TGT CAA AAG ACC TCC CTC CGG GTA AAC TTC GAG GAC ATC GGC TGG GAC                    192 Cys Gln Lys Thr Ser Leu Arg Val Asn Phe Glu Asp Ile Gly Trp Asp 10                    15                    20</p> <p>AGC TGG ATC ATT GCA CCC AAG GAG TAT GAA GGC TAC GAG TGT AAG GGC                    240 Ser Trp Ile Ile Ala Pro Lys Glu Tyr Glu Ala Tyr Glu Cys Lys Gly 25                    30                    35</p> <p>GCG TGC TTC TTC CCC TTG GCT GAC GAT GTG AGC CGG ACG AAA CAC GCT                    288 Gly Cys Phe Phe Pro Leu Ala Asp Asp Val Thr Pro Thr Lys His Ala 40                    45                    50                    55</p> <p>ATC GTG CAG ACC CTG GTG CAT CTC AAG TTC CCC ACA AAG CTG GGC AAG                    336 Ile Val Gln Thr Leu Val His Leu Lys Phe Pro Thr Lys Val Gly Lys 60                    65                    70</p> <p>GCC TGC TGT GTG CCC ACC AAA CTG AGC CCC ATC TCC GTC CTC TAC AAG                    384 Ala Cys Cys Val Pro Thr Lys Leu Ser Pro Ile Ser Val Leu Tyr Lys 75                    80                    85</p> <p>GAT GAC ATC CGG CTG CCC ACC CTC AAG TAC CAT TAC GAG GGC ATG AGC                    432 Asp Asp Met Cys Val Pro Thr Leu Lys Tyr His Tyr Glu Cys Met Ser 90                    95                    100</p> <p>GTC GCA GAG TCT CGG TCC AGG TACTATCTGC CTGCCGG                    470 Val Ala Glu Cys Gly Cys Arg 105                    110</p> <p><b>(57) Abstract</b></p> <p>Purified BMP-9 proteins and processes for producing them are disclosed. The proteins may be used in the treatment of bone and cartilage defects and in wound healing and related tissue repair.</p>			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FI	Finland	ML	Mall
AU	Australia	FR	France	MN	Mongolia
BB	Barbados	GA	Gabon	MR	Mauritania
BE	Belgium	GB	United Kingdom	MW	Malawi
BF	Burkina Faso	GN	Guinea	NL	Netherlands
BG	Bulgaria	GR	Greece	NO	Norway
BJ	Benin	HU	Hungary	PL	Poland
BR	Brazil	IE	Ireland	RO	Romania
CA	Canada	IT	Italy	RU	Russian Federation
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark	MG	Madagascar		
ES	Spain				

**BMP-9 COMPOSITIONS**

The present invention relates to a novel family of purified proteins designated BMP-9 proteins and processes for obtaining them. These proteins may be used to induce bone and/or cartilage formation and in wound healing and tissue repair.

The murine BMP-9 DNA sequence (SEQ ID NO: 1), and amino acid sequence (SEQ ID NO: 2) are set forth in Figure 1. Human BMP-9 sequence is set forth in Figure 3 (SEQ ID NO: 8 and SEQ ID NO: 9). It is contemplated that BMP-9 proteins are capable of inducing the formation of cartilage and/or bone. BMP-9 proteins may be further characterized by the ability to demonstrate cartilage and/or bone formation activity in the rat bone formation assay described below.

Murine BMP-9 is characterized by comprising amino acid #319 to #428 of Figure 1 (SEQ ID NO: 2 amino acids #1-110). Murine BMP-9 may be produced by culturing a cell transformed with a DNA sequence comprising nucleotide #610 to nucleotide #1893 as shown in Figure 1 (SEQ ID NO: 1) and recovering and purifying from the culture medium a protein characterized by the amino acid sequence comprising amino acid #319 to #428 as shown in Figure 1 (SEQ ID NO: 2) substantially free from other proteinaceous materials with which it is co-produced.

Human BMP-9 is expected to be homologous to murine BMP-9 and is characterized by comprising amino acid #1 (Ser, Ala, Gly) to #110 of Figure 3 (SEQ ID NO: 9) (Arg). The invention includes methods for obtaining the DNA sequences encoding human BMP-9. This method entails utilizing the murine BMP-9 nucleotide sequence or portions thereof to design probes to screen libraries for the human gene or fragments thereof using standard techniques. Human BMP-9 may be produced by culturing

a cell transformed with the BMP-9 DNA sequence and recovering and purifying BMP-9 from the culture medium. The expressed protein is isolated, recovered, and purified from the culture medium. The purified expressed protein is substantially free from other proteinaceous materials with which it is co-produced, as well as from other contaminants. The recovered purified protein is contemplated to exhibit cartilage and/or bone formation activity. The proteins of the invention may be further characterized by the ability to demonstrate cartilage and/or bone formation activity in the rat bone formation assay described below.

Human BMP-9 may be produced by culturing a cell transformed with a DNA sequence comprising nucleotide #124 to #453 as shown in SEQ ID NO: 8 and recovering and purifying from the culture medium a protein characterized by the amino acid sequence of SEQ ID NO: 9 from amino acid #1 to amino acid #110 substantially free from other proteinaceous materials with which it is co-produced.

Another aspect of the invention provides pharmaceutical compositions containing a therapeutically effective amount of a BMP-9 protein in a pharmaceutically acceptable vehicle or carrier. BMP-9 compositions of the invention may be used in the formation of cartilage. These compositions may further be utilized for the formation of bone. BMP-9 compositions may also be used for wound healing and tissue repair. Compositions of the invention may further include at least one other therapeutically useful agent such as the BMP proteins BMP-1, BMP-2, BMP-3, BMP-4, BMP-5, BMP-6, and BMP-7 disclosed for instance in PCT publications WO88/00205, WO89/10409, and WO90/11366, and BMP-8, disclosed in U.S. application Ser. No. 07/641,204 filed January 15, 1991, Ser. No. 07/525,357 filed May 16, 1990, and Ser. No. 07/800,364 filed November 20, 1991.

The compositions of the invention may comprise, in addition to a BMP-9 protein, other therapeutically useful agents including growth factors such as epidermal growth factor (EGF), fibroblast growth factor (FGF), transforming growth

factor (TGF- $\alpha$  and TGF- $\beta$ ), and insulin-like growth factor (IGF). The compositions may also include an appropriate matrix for instance, for supporting the composition and providing a surface for bone and/or cartilage growth. The matrix may 5 provide slow release of the osteoinductive protein and/or the appropriate environment for presentation thereof.

The BMP-9 compositions may be employed in methods for treating a number of bone and/or cartilage defects, periodontal disease and various types of wounds. These methods, according 10 to the invention, entail administering to a patient needing such bone and/or cartilage formation wound healing or tissue repair, an effective amount of a BMP-9 protein. These methods may also entail the administration of a protein of the invention in conjunction with at least one of the novel BMP 15 proteins disclosed in the co-owned applications described above. In addition, these methods may also include the administration of a BMP-9 protein with other growth factors including EGF, FGF, TGF- $\alpha$ , TGF- $\beta$ , and IGF.

Still a further aspect of the invention are DNA sequences 20 coding for expression of a BMP-9 protein. Such sequences include the sequence of nucleotides in a 5' to 3' direction illustrated in Figure 1 (SEQ ID NO: 1) and Figure 3 (SEQ ID NO: 8) or DNA sequences which hybridize under stringent conditions with the DNA sequences of Figure 1 or 3 and encode a protein 25 having the ability to induce the formation of cartilage and/or bone. Finally, allelic or other variations of the sequences of Figure 1 or 3, whether such nucleotide changes result in changes in the peptide sequence or not, are also included in the present invention.

A further aspect of the invention includes vectors 30 comprising a DNA sequence as described above in operative association with an expression control sequence therefor. These vectors may be employed in a novel process for producing a BMP-9 protein of the invention in which a cell line 35 transformed with a DNA sequence encoding a BMP-9 protein in

operative association with an expression control sequence therefor, is cultured in a suitable culture medium and a BMP-9 protein is recovered and purified therefrom. This process may employ a number of known cells both prokaryotic and eukaryotic 5 as host cells for expression of the polypeptide.

Other aspects and advantages of the present invention will be apparent upon consideration of the following detailed description and preferred embodiments thereof.

10 Brief Description of the Drawing

FIG. 1 comprises DNA sequence and derived amino acid sequence of murine BMP-9 from clone ML14a further described below.

15 FIG. 2 comprises DNA sequence and derived amino acid sequence of human BMP-4 from lambda U2OS-3 ATCC #40342.

FIG. 3 comprises DNA sequence and derived amino acid sequence of human BMP-9 from λ FIX/H6111 ATCC # 75252.

20 Detailed Description of the Invention

The murine BMP-9 nucleotide sequence (SEQ ID NO: 1) and encoded amino acid sequence (SEQ ID NO: 2) are depicted in Figure 1. Purified murine BMP-9 proteins of the present invention are produced by culturing a host cell transformed with 25 a DNA sequence comprising the DNA coding sequence of Figure 1 (SEQ ID NO: 1) from nucleotide #610 to nucleotide #1893 and recovering and purifying from the culture medium a protein which contains the amino acid sequence or a substantially homologous sequence as represented by amino acid #319 to #428 30 of Figure 1 (SEQ ID NO: 2). The BMP-9 proteins recovered from the culture medium are purified by isolating them from other proteinaceous materials from which they are co-produced and from other contaminants present.

Human BMP-9 nucleotide and amino acid sequence is depicted in SEQ ID No: 8 and 9. Mature human BMP-9 is expected to comprise amino acid #1 (Ser, Ala, Gly) to #110 (Arg).

Human BMP-9 may be produced by culturing a cell  
5 transformed with a DNA sequence comprising nucleotide #124 to  
#453 as shown in SEQ ID NO: 8 and recovering and purifying from  
the culture medium a protein characterized by the amino acid  
sequence of SEQ ID NO: 9 from amino acid #1 to amino acid #110  
substantially free from other proteinaceous materials with  
10 which it is co-produced.

BMP-9 proteins may be characterized by the ability to  
induce the formation of cartilage. BMP-9 proteins may be  
further characterized by the ability to induce the formation of  
15 bone. BMP-9 proteins may be further characterized by the  
ability to demonstrate cartilage and/or bone formation activity  
in the rat bone formation assay described below.

The BMP-9 proteins provided herein also include factors  
encoded by the sequences similar to those of Figure 1 and 3  
20 (SEQ ID NO's: 1 and 8), but into which modifications are  
naturally provided (e.g. allelic variations in the nucleotide  
sequence which may result in amino acid changes in the  
polypeptide) or deliberately engineered. For example,  
synthetic polypeptides may wholly or partially duplicate  
continuous sequences of the amino acid residues of Figure 1 of  
25 Figure 3 (SEQ ID NO's: 2 and 9). These sequences, by virtue of  
sharing primary, secondary, or tertiary structural and  
conformational characteristics with bone growth factor  
polypeptides of Figure 1 and Figure 3 may possess bone growth  
factor biological properties in common therewith. Thus, they  
30 may be employed as biologically active substitutes for  
naturally-occurring BMP-9 and other BMP-9 polypeptides in  
therapeutic processes.

Other specific mutations of the sequences of BMP-9  
proteins described herein involve modifications of  
35 glycosylation sites. These modifications may involve O-linked

or N-linked glycosylation sites. For instance, the absence of glycosylation or only partial glycosylation results from amino acid substitution or deletion at asparagine-linked glycosylation recognition sites. The asparagine-linked glycosylation recognition sites comprise tripeptide sequences which are specifically recognized by appropriate cellular glycosylation enzymes. These tripeptide sequences are either asparagine-X-threonine or asparagine-X-serine, where X is usually any amino acid. A variety of amino acid substitutions or deletions at one or both of the first or third amino acid positions of a glycosylation recognition site (and/or amino acid deletion at the second position) results in non-glycosylation at the modified tripeptide sequence.

The present invention also encompasses the novel DNA sequences, free of association with DNA sequences encoding other proteinaceous materials, and coding on expression for BMP-9 proteins. These DNA sequences include those depicted in Figure 1 or Figure 3 (SEQ ID NO's: 1 and 8) in a 5' to 3' direction and those sequences which hybridize thereto under stringent hybridization conditions [see, T. Maniatis et al, Molecular Cloning (A Laboratory Manual), Cold Spring Harbor Laboratory (1982), pages 387 to 389] and encode a protein having cartilage and/or bone inducing activity.

Similarly, DNA sequences which code for BMP-9 proteins coded for by the sequences of Figure 1 or Figure 3, but which differ in codon sequence due to the degeneracies of the genetic code or allelic variations (naturally-occurring base changes in the species population which may or may not result in an amino acid change) also encode the novel factors described herein. Variations in the DNA sequences of Figure 1 or Figure 3 (SEQ ID NO: 1 and 8) which are caused by point mutations or by induced modifications (including insertion, deletion, and substitution) to enhance the activity, half-life or production of the polypeptides encoded are also encompassed in the invention.

Another aspect of the present invention provides a novel

method for producing BMP-9 proteins. The method of the present invention involves culturing a suitable cell line, which has been transformed with a DNA sequence encoding a BMP-9 protein of the invention, under the control of known regulatory sequences. The transformed host cells are cultured and the BMP-9 proteins recovered and purified from the culture medium. The purified proteins are substantially free from other proteins with which they are co-produced as well as from other contaminants.

Suitable cells or cell lines may be mammalian cells, such as Chinese hamster ovary cells (CHO). The selection of suitable mammalian host cells and methods for transformation, culture, amplification, screening, product production and purification are known in the art. See, e.g., Gething and Sambrook, Nature, 293:620-625 (1981), or alternatively, Kaufman et al, Mol. Cell. Biol., 5(7):1750-1759 (1985) or Howley et al, U.S. Patent 4,419,446. Another suitable mammalian cell line, which is described in the accompanying examples, is the monkey COS-1 cell line. The mammalian cell CV-1 may also be suitable.

Bacterial cells may also be suitable hosts. For example, the various strains of E. coli (e.g., HB101, MC1061) are well-known as host cells in the field of biotechnology. Various strains of B. subtilis, Pseudomonas, other bacilli and the like may also be employed in this method.

Many strains of yeast cells known to those skilled in the art may also be available as host cells for expression of the polypeptides of the present invention. Additionally, where desired, insect cells may be utilized as host cells in the method of the present invention. See, e.g. Miller et al, Genetic Engineering, 8:277-298 (Plenum Press 1986) and references cited therein.

Another aspect of the present invention provides vectors for use in the method of expression of these novel BMP-9 polypeptides. Preferably the vectors contain the full novel

DNA sequences described above which encode the novel factors of the invention. Additionally the vectors also contain appropriate expression control sequences permitting expression of the BMP-9 protein sequences. Alternatively, vectors 5 incorporating modified sequences as described above are also embodiments of the present invention. The vectors may be employed in the method of transforming cell lines and contain selected regulatory sequences in operative association with the DNA coding sequences of the invention which are capable of 10 directing the replication and expression thereof in selected host cells. Regulatory sequences for such vectors are known to those skilled in the art and may be selected depending upon the host cells. Such selection is routine and does not form part of the present invention.

15 A protein of the present invention, which induces cartilage and/or bone formation in circumstances where bone is not normally formed, has application in the healing of bone fractures and cartilage defects in humans and other animals. Such a preparation employing a BMP-9 protein may have 20 prophylactic use in closed as well as open fracture reduction and also in the improved fixation of artificial joints. De novo bone formation induced by an osteogenic agent contributes to the repair of congenital, trauma induced, or oncologic resection induced craniofacial defects, and also is useful in 25 cosmetic plastic surgery. A BMP-9 protein may be used in the treatment of periodontal disease, and in other tooth repair processes. Such agents may provide an environment to attract bone-forming cells, stimulate growth of bone-forming cells or induce differentiation of progenitors of bone-forming cells. 30 BMP-9 polypeptides of the invention may also be useful in the treatment of osteoporosis. A variety of osteogenic, cartilage-inducing and bone inducing factors have been described. See, e.g. European patent applications 148,155 and 169,016 for discussions thereof.

The proteins of the invention may also be used in wound healing and related tissue repair. The types of wounds include, but are not limited to burns, incisions and ulcers. (See, e.g. PCT Publication WO84/01106 for discussion of wound 5 healing and related tissue repair).

It is further contemplated that proteins of the invention may increase neuronal survival and therefore be useful in transplantation and treatment of conditions exhibiting a decrease in neuronal survival.

10 A further aspect of the invention is a therapeutic method and composition for repairing fractures and other conditions related to cartilage and/or bone defects or periodontal diseases. The invention further comprises therapeutic methods and compositions for wound healing and tissue repair. Such 15 compositions comprise a therapeutically effective amount of at least one of the BMP-9 proteins of the invention in admixture with a pharmaceutically acceptable vehicle, carrier or matrix.

It is expected that the proteins of the invention may act 20 in concert with or perhaps synergistically with other related proteins and growth factors. Further therapeutic methods and compositions of the invention therefore comprise a therapeutic amount of at least one BMP-9 protein of the invention with a therapeutic amount of at least one of the other BMP proteins disclosed in co-owned applications described above. Such 25 combinations may comprise separate molecules of the BMP proteins or heteromolecules comprised of different BMP moieties. For example, a method and composition of the invention may comprise a disulfide linked dimer comprising a BMP-9 protein subunit and a subunit from one of the "BMP" 30 proteins described above. A further embodiment may comprise a heterodimer of BMP-9 moieties. Further, BMP-9 proteins may be combined with other agents beneficial to the treatment of the bone and/or cartilage defect, wound, or tissue in question. These agents include various growth factors such as epidermal 35 growth factor (EGF), platelet derived growth factor (PDGF),

transforming growth factors (TGF- $\alpha$  and TGF- $\beta$ ), and insulin-like growth factor (IGF).

The preparation and formulation of such physiologically acceptable protein compositions, having due regard to pH, isotonicity, stability and the like, is within the skill of the art. The therapeutic compositions are also presently valuable for veterinary applications due to the lack of species specificity in BMP proteins. Particularly domestic animals and thoroughbred horses in addition to humans are desired patients for such treatment with BMP-9 of the present invention.

The therapeutic method includes administering the composition topically, systemically, or locally as an implant or device. When administered, the therapeutic composition for use in this invention is, of course, in a pyrogen-free, physiologically acceptable form. Further, the composition may desirably be encapsulated or injected in a viscous form for delivery to the site of bone, cartilage or tissue damage. Topical administration may be suitable for wound healing and tissue repair. Therapeutically useful agents other than the BMP-9 proteins which may also optionally be included in the composition as described above, may alternatively or additionally, be administered simultaneously or sequentially with the BMP composition in the methods of the invention.

Preferably for bone and/or cartilage formation, the composition would include a matrix capable of delivering BMP-9 or other BMP proteins to the site of bone and/or cartilage damage, providing a structure for the developing bone and cartilage and optimally capable of being resorbed into the body. The matrix may provide slow release of BMP-9 and/or the appropriate environment for presentation thereof. Such matrices may be formed of materials presently in use for other implanted medical applications.

The choice of matrix material is based on biocompatibility, biodegradability, mechanical properties, cosmetic appearance and interface properties. The particular

application of the BMP-9 compositions will define the appropriate formulation. Potential matrices for the compositions may be biodegradable and chemically defined calcium sulfate, tricalciumphosphate, hydroxyapatite, 5 polylactic acid and polyanhydrides. Other potential materials are biodegradable and biologically well defined, such as bone or dermal collagen. Further matrices are comprised of pure proteins or extracellular matrix components. Other potential matrices are nonbiodegradable and chemically defined, such as 10 sintered hydroxyapatite, bioglass, aluminates, or other ceramics. Matrices may be comprised of combinations of any of the above mentioned types of material, such as polylactic acid and hydroxyapatite or collagen and tricalciumphosphate. The 15 bioceramics may be altered in composition, such as in calcium-aluminate-phosphate and processing to alter pore size, particle size, particle shape, and biodegradability.

The dosage regimen will be determined by the attending physician considering various factors which modify the action 20 of the BMP-9 protein, e.g. amount of bone weight desired to be formed, the site of bone damage, the condition of the damaged bone, the size of a wound, type of damaged tissue, the patient's age, sex, and diet, the severity of any infection, time of administration and other clinical factors. The dosage 25 may vary with the type of matrix used in the reconstitution and the types of BMP proteins in the composition. The addition of other known growth factors, such as IGF I (insulin like growth factor I), to the final composition, may also effect the dosage. Progress can be monitored by periodic assessment of bone growth and/or repair, for example, x-rays, 30 histomorphometric determinations and tetracycline labeling.

The following examples illustrate practice of the present invention in recovering and characterizing murine BMP-9 protein and employing it to recover the human and other BMP-9 proteins, obtaining the human proteins and expressing the proteins via 35 recombinant techniques.

## EXAMPLE I

Murine BMP-9

750,000 recombinants of a mouse liver cDNA library made in the vector lambdaZAP (Stratagene/Catalog #935302) are plated and duplicate nitrocellulose replicas made. A fragment of human BMP-4 DNA corresponding to nucleotides 1330-1627 of Figure 2 (SEQ ID NO: 3) (the human BMP-4 sequence) is <sup>32</sup>P-labeled by the random priming procedure of Feinberg et al. [Anal. Biochem. 132: 6-13 (1983)] and hybridized to both sets of filters in SHB at 60°C for 2 to 3 days. Both sets of filters are washed under reduced stringency conditions (4X SSC, 0.1% SDS at 60°C). Many duplicate hybridizing recombinants of various intensities (approximately 92) are noted. 50 of the strongest hybridizing recombinant bacteriophage are plaque purified and their inserts are transferred to the plasmid Bluescript SK (+/-) according to the *in vivo* excision protocol described by the manufacturer (Stratagene). DNA sequence analysis of several recombinants indicate that they encode a protein homologous to other BMP proteins and other proteins in the TGF- $\beta$  family. The DNA sequence and derived amino acid sequence of one recombinant, designated ML14a, is set forth in Figure 1. (SEQ ID NO: 1)

The nucleotide sequence of clone ML14a contains an open reading frame of 1284 bp, encoding a BMP-9 protein of 428 amino acids. The encoded 428 amino acid BMP-9 protein is contemplated to be the primary translation product as the coding sequence is preceded by 609 bp of 5' untranslated sequence with stop codons in all three reading frames. The 428 amino acid sequence predicts a BMP-9 protein with a molecular weight of 48,000 daltons.

Based on knowledge of other BMP proteins and other proteins within the TGF- $\beta$  family, it is predicted that the precursor polypeptide would be cleaved at the multibasic sequence ARG-ARG-LYS-ARG in agreement with a proposed consensus

proteolytic processing sequence of ARG-X-X-ARG. Cleavage of the BMP-9 precursor polypeptide at this location would generate a 110 amino acid mature peptide beginning with the amino acid SER at position #319. The processing of BMP-9 into the mature 5 form is expected to involve dimerization and removal of the N-terminal region in a manner analogous to the processing of the related protein TGF- $\beta$  [L.E. Gentry, et al., Molec. & Cell. Biol. 8:4162 (1988); R. Deryck, et al., Nature 316:701 (1985)].

10 It is contemplated therefore that the mature active species of murine BMP-9 comprises a homodimer of 2 polypeptide subunits, each subunit comprising amino acids #319-#428 with a predicted molecular weight of approximately 12,000 daltons. Further active species are contemplated comprising amino acids 15 #326 - #428 thereby including the first conserved cysteine residue. As with other members of the BMP and TGF- $\beta$  family of proteins, the carboxy-terminal region of the BMP-9 protein exhibits greater sequence conservation than the more amino-terminal portion. The percent amino acid identity of the 20 murine BMP-9 protein in the cysteine-rich C-terminal domain (amino acids #326 - #428) to the corresponding region of other human BMP proteins and other proteins within the TGF- $\beta$  family is as follows: BMP-2, 53%; BMP-3, 43%; BMP-4, 53%; BMP-5, 55%; BMP-6, 55%; BMP-7, 53%; Vgl, 50%; GDF-1, 43%; TGF- $\beta$ 1, 32%; TGF- $\beta$ 2, 34%; TGF- $\beta$ 3, 34%; inhibin  $\beta$ (B), 34%; and inhibin  $\beta$ (A), 42%.

#### EXAMPLE II

##### Human BMP-9

30 Murine and human osteoinductive factor genes are presumed to be significantly homologous, therefore the murine coding sequence or a portion thereof is used as a probe to screen a human genomic library or as a probe to identify a human cell line or tissue which synthesizes the analogous human cartilage 35 and/or bone protein. A human genomic library (Toole et al., supra) may be screened with such a probe, and presumptive

positives isolated and DNA sequence obtained. Evidence that this recombinant encodes a portion of the human BMP-9 relies of the murine/human protein and gene structure homologies.

Once a recombinant bacteriophage containing DNA encoding portion of the human cartilage and/or bone inductive factor molecule is obtained, the human coding sequence can be used as a probe to identify a human cell line or tissue which synthesizes BMP-9. Alternatively, the murine coding sequence can be used as a probe to identify such human cell line or tissue. Briefly described, RNA is extracted from a selected cell or tissue source and either electrophoresed on a formaldehyde agarose gel and transferred to nitrocellulose, or reacted with formaldehyde and spotted on nitrocellulose directly. The nitrocellulose is then hybridized to a probe derived from a coding sequence of the murine or human BMP-9. mRNA is selected by oligo (dT) cellulose chromatography and cDNA is synthesized and cloned in lambda gt10 or lambda ZAP by established techniques (Toole et al., *supra*).

Additional methods known to those skilled in the art may be used to isolate the human and other species' BMP-9 proteins of the invention.

#### A. Isolation of Human BMP-9 DNA

One million recombinants of a human genomic library constructed in the vector λFIX (Stratagene catalog # 944201) are plated and duplicate nitrocellulose replicas made. Two oligonucleotides probes designed on the basis of nucleotides #1665-#1704 and #1837-#1876 of the sequence set forth in Figure 1 (SEQ ID NO:1) are synthesized on an automated DNA synthesizer. The sequence of these two oligonucleotides is indicated below:

#1: CTATGAGTGAAAGGGGTTGCTTCTTCCCATTGGCTGAT

#2: GTGCCAACCTCAAGTACCACTATGAGGGGATGAGTGTGG.

These two oligonucleotide probes are radioactively labeled with

$\gamma^{32}$ P-ATP and each is hybridized to one set of the duplicate nitrocellulose replicas in SHB at 65°C and washed with 1X SSC, 0.1% SDS at 65°C. Three recombinants which hybridize to both oligonucleotide probes are noted. All three positively hybridizing recombinants are plaque purified, bacteriophage plate stocks are prepared and bacteriophage DNA is isolated from each. The oligonucleotide hybridizing regions of one of these recombinants, designated HG111, is localized to a 1.2 kb Pst I/Xba I fragment. This fragment is subcloned into a plasmid vector (pGEM-3) and DNA sequence analysis is performed.

HG111 was deposited with the ATCC, 12301 Parklawn Drive, Rockville, Maryland USA on June 16, 1992 under the requirements of the Budapest Treaty and designated as ATCC # 75252. This subclone is designated pGEM-111. A portion of the DNA sequence of clone pGEM-111 is set forth in Figure 3 (SEQ ID NO:8/ HUMAN BMP-9 sequence). This sequence encodes the entire mature region of human BMP-9 and a portion of the propeptide. It should be noted that this sequence consists of preliminary data. Particularly, the propeptide region is subject to further analysis and characterization. For example, nucleotides #1 through #3 (TGA) encode a translational stop which may be incorrect due to the preliminary nature of the sequence. It is predicted that additional sequences present in both pGEM-111 (the 1.2 kb PstI/XbaI fragment of HG111 subcloned into pGEM) and HG111 encode additional amino acids of the human BMP-9 propeptide region. Based on knowledge of other BMPs and other proteins within the TGF- $\beta$  family, it is predicted that the precursor polypeptide would be cleaved at the multibasic sequence ARG-ARG-LYS-ARG (amino acids # -4 through # -1 of SEQUENCE ID NO:9) in agreement with a proposed consensus proteolytic processing sequence ARG-X-X-ARG. Cleavage of the human BMP-9 precursor polypeptide at this location would generate a 110 amino acid mature peptide beginning with the amino acid SER at position #1 of SEQUENCE ID NO:9 (encoded by

nucleotides #124 through #126 of SEQUENCE ID NO:8). The processing of human BMP-9 into the mature form is expected to involve dimerization and removal of the N-terminal region in a manner analogous to the processing of the related protein TGF- $\beta$  5 [L.E. Gentry, et al., Molec. & Cell. Biol. 8:4162 (1988); R. Deryck, et al., Nature 316:701 (1985)].

It is contemplated therefore that the mature active species of human BMP-9 comprises a homodimer of two polypeptide subunits, each subunit comprising amino acids #1 through #110 10 of SEQUENCE ID NO:9, with a predicted molecular weight of 12,000 daltons. Further active species are contemplated comprising amino acids #8 through #110 thereby including the first conserved cysteine residue. As with other members of the 15 BMP and TGF- $\beta$  family of proteins, the carboxy-terminal portion of the human BMP-9 sequence exhibits greater sequence conservation than the amino-terminal portion. the percent amino acid identity of the human BMP-9 protein in the cysteine-rich C-terminal domain (amino acids #8 through #110) to the corresponding region of other human BMP proteins and other 20 proteins within the TGF- $\beta$  family is as follows: BMP-2, 52%; BMP-3, 40%; BMP-4, 52%; BMP-5, 55%; BMP-6, 55%; BMP-7, 53%; murine BMP-9, 97%; Vg1, 50%; GDF-1, 44%; TGF- $\beta$ 1, 32%; TGF- $\beta$ 2, 32%; TGF- $\beta$ 3, 32%; inhibin  $\beta$  (B), 35%; and inhibin  $\beta$  (A), 41%.

25 EXAMPLE III

Rosen Modified Sampath-Reddi Assay

A modified version of the rat bone formation assay described in Sampath and Reddi, Proc. Natl. Acad. Sci. U.S.A., 30 80:6591-6595 (1983) is used to evaluate bone and/or cartilage activity of the BMP proteins. This modified assay is herein called the Rosen-modified Sampath-Reddi assay. The ethanol precipitation step of the Sampath-Reddi procedure is replaced by dialyzing (if the composition is a solution) or diafiltrating (if the composition is a suspension) the fraction to be assayed 35 against water. The solution or suspension is then redissolved

in 0.1 % TFA, and the resulting solution added to 20mg of rat matrix. A mock rat matrix sample not treated with the protein serves as a control. This material is frozen and lyophilized and the resulting powder enclosed in #5 gelatin capsules. The 5 capsules are implanted subcutaneously in the abdominal thoracic area of 21 - 49 day old male Long Evans rats. The implants are removed after 7 - 14 days. Half of each implant is used for alkaline phosphatase analysis [See, A. H. Reddi et al., Proc. Natl Acad Sci., 69:1601 (1972)].

10 The other half of each implant is fixed and processed for histological analysis. 1 $\mu$ m glycolmethacrylate sections are stained with Von Kossa and acid fuchsin to score the amount of induced bone and cartilage formation present in each implant. The terms +1 through +5 represent the area of each 15 histological section of an implant occupied by new bone and/or cartilage cells and matrix. A score of +5 indicates that greater than 50% of the implant is new bone and/or cartilage produced as a direct result of protein in the implant. A score of +4, +3, +2 and +1 would indicate that greater than 40%, 20%, 20% and 10% respectively of the implant contains new 20 cartilage and/or bone. In a modified scoring method, three non-adjacent sections are evaluated from each implant and averaged. "+/-" indicates tentative identification of 25 cartilage or bone; "+1" indicates >10% of each section being new cartilage or bone; "+2", >25%; "+3", >50%; "+4", -75%; "+5", >80%. A "--" indicates that the implant is not recovered.

It is contemplated that the dose response nature of the 30 BMP-9 containing samples of the matrix samples will demonstrate that the amount of bone and/or cartilage formed increases with the amount of BMP-9 in the sample. It is contemplated that the control samples will not result in any bone and/or cartilage formation.

As with other cartilage and/or bone inductive proteins such as the above-mentioned "BMP" proteins, the bone and/or 35 cartilage formed is expected to be physically confined to the

space occupied by the matrix. Samples are also analyzed by SDS gel electrophoresis and isoelectric focusing followed by autoradiography. The activity is correlated with the protein bands and pI. To estimate the purity of the protein in a particular fraction an extinction coefficient of 1 OD/mg-cm is used as an estimate for protein and the protein is run on SDS PAGE followed by silver staining or radioiodination and autoradiography.

10       EXAMPLE IV

Expression of BMP-9

In order to produce murine, human or other mammalian BMP-9 proteins, the DNA encoding it is transferred into an appropriate expression vector and introduced into mammalian cells or other preferred eukaryotic or prokaryotic hosts by conventional genetic engineering techniques. The preferred expression system for biologically active recombinant human BMP-9 is contemplated to be stably transformed mammalian cells.

One skilled in the art can construct mammalian expression vectors by employing the sequence of Figure 1 (SEQ ID NO: 1) or Figure 3 (SEQ ID NO: 8), or other DNA sequences encoding BMP-9 proteins or other modified sequences and known vectors, such as pCD [Okayama et al., Mol. Cell Biol., 2:161-170 (1982)], pJL3, pJL4 [Gough et al., EMBO J., 4:645-653 (1985)] and pMT2 CXM.

The mammalian expression vector pMT2 CXM is a derivative of p91023 (b) (Wong et al., Science 228:810-815, 1985) differing from the latter in that it contains the ampicillin resistance gene in place of the tetracycline resistance gene and further contains a XhoI site for insertion of cDNA clones. The functional elements of pMT2 CXM have been described (Kaufman, R.J., 1985, Proc. Natl. Acad. Sci. USA 82:689-693) and include the adenovirus VA genes, the SV40 origin of replication including the 72 bp enhancer, the adenovirus major late promoter including a 5' splice site and the majority of

the aden virus tripartite leader sequence present on adenovirus late mRNAs, a 3' splice acceptor site, a DHFR insert, the SV40 early polyadenylation site (SV40), and pBR322 sequences needed for propagation in *E. coli*.

5 Plasmid pMT2 CXM is obtained by EcoRI digestion of pMT2-VWF, which has been deposited with the American Type Culture Collection (ATCC), Rockville, MD (USA) under accession number ATCC 67122. EcoRI digestion excises the cDNA insert present in pMT2-VWF, yielding pMT2 in linear form which can be ligated and  
10 used to transform *E. coli* HB 101 or DH-5 to ampicillin resistance. Plasmid pMT2 DNA can be prepared by conventional methods. pMT2 CXM is then constructed using loopout/in mutagenesis [Morinaga, et al., *Biotechnology* 84: 636 (1984)]. This removes bases 1075 to 1145 relative to the Hind III site  
15 near the SV40 origin of replication and enhancer sequences of pMT2. In addition it inserts the following sequence:

5' PO-CATGGGCAGCTCGAG-3' (SEQ ID NO: 5)

at nucleotide 1145. This sequence contains the recognition site for the restriction endonuclease Xho I. A derivative of pMT2CXM, termed pMT23, contains recognition sites for the restriction endonucleases PstI, Eco RI, SalI and XhoI. Plasmid pMT2 CXM and pMT23 DNA may be prepared by conventional methods.

25 pEMC2b1 derived from pMT21 may also be suitable in practice of the invention. pMT21 is derived from pMT2 which is derived from pMT2-VWF. As described above EcoRI digestion excises the cDNA insert present in pMT-VWF, yielding pMT2 in linear form which can be ligated and used to transform *E. coli* HB 101 or DH-5 to ampicillin resistance. Plasmid pMT2 DNA can be prepared by conventional methods.

30 pMT21 is derived from pMT2 through the following two modifications. First, 76 bp of the 5' untranslated region of the DHFR cDNA including a stretch of 19 G residues from G/C tailing for cDNA cloning is deleted. In this process, a XhoI site is inserted to obtain the following sequence immediately

20

(SEQ ID NO: 6)

Second, a unique *Cla*I site is introduced by digestion with *Eco*RV and *Xba*I, treatment with Klenow fragment of DNA polymerase I, and ligation to a *Cla*I linker (CATCGATG). This deletes a 250 bp segment from the adenovirus associated RNA (VAI) region but does not interfere with VAI RNA gene expression or function. pMT21 is digested with *Eco*RI and *Xba*I, and used to derive the vector pEMC2B1.

A portion of the EMCV leader is obtained from pMT2-ECAT1 [S.K. Jung, et al, J. Virol. **63**:1651-1660 (1989)] by digestion with Eco RI and PstI, resulting in a 2752 bp fragment. This fragment is digested with TaqI yielding an Eco RI-TaqI fragment of 508 bp which is purified by electrophoresis on low melting agarose gel. A 68 bp adapter and its complementary strand are synthesized with a 5' TaqI protruding end and a 3' XhoI protruding end which has the following sequence:

20 5'-CGAGGTTAAAAACGTCTAGGCCCGAACCACGGGGACGTGGTTTCCTT  
TagI

**GAAAAACACGATTGC-3'**  
XhoI (SEQ ID NO: 7)

25 This sequence matches the EMC virus leader sequence from  
nucleotide 763 to 827. It also changes the ATG at position 10  
within the EMC virus leader to an ATT and is followed by a XhoI  
site. A three way ligation of the pMT21 Eco RI-XhoI fragment,  
30 the EMC virus EcoRI-TaqI fragment, and the 68 bp

oligonucleotide adapter TaqI-XbaI adapter resulting in the vector pEMC2 $\beta$ 1.

This vector contains the SV40 origin of replication and enhancer, the adenovirus major late promoter, a cDNA copy of the majority of the adenovirus tripartite leader sequence, a small hybrid intervening sequence, an SV40 polyadenylation

signal and the adenovirus VA I gene, DHFR and  $\beta$ -lactamase markers and an EMC sequence, in appropriate relationships to direct the high level expression of the desired cDNA in mammalian cells.

5       The construction of vectors may involve modification of the BMP-9 DNA sequences. For instance, BMP-9 cDNA can be modified by removing the non-coding nucleotides on the 5' and 3' ends of the coding region. The deleted non-coding nucleotides may or may not be replaced by other sequences known  
10      to be beneficial for expression. These vectors are transformed into appropriate host cells for expression of BMP-9 proteins.

One skilled in the art can manipulate the sequences of Figure 1 or Figure 3 (SEQ ID NO: 1 and 8) by eliminating or replacing the mammalian regulatory sequences flanking the  
15      coding sequence with bacterial sequences to create bacterial vectors for intracellular or extracellular expression by bacterial cells. For example, the coding sequences could be further manipulated (e.g. ligated to other known linkers or modified by deleting non-coding sequences therefrom or altering  
20      nucleotides therein by other known techniques). The modified BMP-9 coding sequence could then be inserted into a known bacterial vector using procedures such as described in T. Taniguchi et al., Proc. Natl Acad. Sci. USA, 77:5230-5233 (1980). This exemplary bacterial vector could then be  
25      transformed into bacterial host cells and a BMP-9 protein expressed thereby. For a strategy for producing extracellular expression of BMP-9 proteins in bacterial cells, see, e.g. European patent application EPA 177,343.

Similar manipulations can be performed for the  
30      construction of an insect vector [See, e.g. procedures described in published European patent application 155,476] for expression in insect cells. A yeast vector could also be constructed employing yeast regulatory sequences for intracellular or extracellular expression of the factors of the present invention by yeast cells. [See, e.g., procedures

described in published PCT application WO86/00639 and European patent application EPA 123,289].

A method for producing high levels of a BMP-9 protein of the invention in mammalian cells may involve the construction 5 of cells containing multiple copies of the heterologous BMP-9 gene. The heterologous gene is linked to an amplifiable marker, e.g. the dihydrofolate reductase (DHFR) gene for which cells containing increased gene copies can be selected for propagation in increasing concentrations of methotrexate (MTX) 10 according to the procedures of Kaufman and Sharp, J. Mol. Biol., 159:601-629 (1982). This approach can be employed with a number of different cell types.

For example, a plasmid containing a DNA sequence for a BMP-9 of the invention in operative association with other 15 plasmid sequences enabling expression thereof and the DHFR expression plasmid pAdA26SV(A)3 [Kaufman and Sharp, Mol. Cell. Biol., 2:1304 (1982)] can be co-introduced into DHFR-deficient CHO cells, DUKX-BII, by various methods including calcium phosphate coprecipitation and transfection, electroporation or 20 protoplast fusion. DHFR expressing transformants are selected for growth in alpha media with dialyzed fetal calf serum, and subsequently selected for amplification by growth in increasing concentrations of MTX (e.g. sequential steps in 0.02, 0.2, 1.0 and 5uM MTX) as described in Kaufman et al., Mol Cell Biol., 5:1750 (1983). Transformants are cloned, and biologically 25 active BMP-9 expression is monitored by the Rosen-modified Sampath - Reddi rat bone formation assay described above in Example III. BMP-9 expression should increase with increasing levels of MTX resistance. BMP-9 polypeptides are characterized 30 using standard techniques known in the art such as pulse labeling with [<sup>35</sup>S] methionine or cysteine and polyacrylamide gel electrophoresis. Similar procedures can be followed to produce other related BMP-9 proteins.

**A. BMP-9 Vector Construction**

In order to produce human BMP-9 proteins of the invention DNA sequences encoding the mature region of the human BMP-9 protein may be joined to DNA sequences encoding the propeptide 5 region of the murine BMP-9 protein. This murine/human hybrid DNA sequence is inserted into an appropriate expression vector and introduced into mammalian cells or other preferred eukaryotic or prokaryotic hosts by conventional genetic engineering techniques. The construction of this murine/human 10 BMP-9 containing expression plasmid is described below.

A derivative of the human BMP-9 sequence (SEQ ID NO:8) comprising the nucleotide sequence from nucleotide #105 to #470 is specifically amplified. The following oligonucleotides are utilized as primers to allow the amplification of nucleotides 15 #105 to #470 of the human BMP-9 sequence (SEQ ID NO:8) from clone pGEM-111 described above.

#3 ATCGGGCCCTTTAGCCAGGCCGAAAGGAG

#4 AGCGAATTCCCCGCAGGCAGATACTACCTG

This procedure generates the insertion of the nucleotide 20 sequence ATCGGGCCCT immediately preceding nucleotide #105 and the insertion of the nucleotide sequence GAATTCGCT immediately following nucleotide #470. The addition of these sequences results in the creation of an Apa I and EcoR I restriction 25 endonuclease site at the respective ends of the specifically amplified DNA fragment. The resulting 374 bp Apa I/EcoR I fragment is subcloned into the plasmid vector pGEM-7zf(+) (Promega<sup>®</sup> catalog# p2251) which has been digested with Apa I and EcoR I. The resulting clone is designated phBMP9mex-1.

30 The following oligonucleotides are designed on the basis of murine BMP-9 sequences (SEQ ID NO:1) and are modified to facilitate the construction of the murine/human expression plasmid referred to above:

#5

35 GATTCCGTGACCACCATGTCCCCTGGGGCTGGTCTAGATGGATACACAGCTGTGGGCC

#6 CCACAGCTGTGTATCCATCTAGACCAGGCCAGGGGACATGGTGGTCGACG  
These oligonucleotides contain complimentary sequences which  
upon addition to each other facilitate the annealing (base  
pairing) of the two individual sequences, resulting in the  
5 formation of a double stranded synthetic DNA linker (designated  
LINK-1) in a manner indicated below:

1 5 10 20 30 40 50 60  
| | | | | | | |  
#5GATTCCGTCGACCACCATGTCCCCCTGGGCCTGGTCTAGATGGATA  
10 CACAGCTGGTGGTACAGGGGACCCCGGACCAGATCTACCTATGTGTCGACACC #6

This DNA linker (LINK-1) contains recognition sequences of  
restriction endonucleases needed to facilitate subsequent  
manipulations required to construct the murine/human expression  
plasmid, as well as sequences required for maximal expression  
15 of heterologous sequences in mammalian cell expression systems.  
More specifically (referring to the sequence numbering of  
oligonucleotide #5/LINK-1): nucleotides #1-#11 comprise  
recognition sequences for the restriction endonucleases BamH I  
and Sal I, nucleotides #11-#15 allow for maximal expression of  
20 heterologous sequences in mammalian cell expression systems,  
nucleotides #16-#31 correspond to nucleotides #610-#625 of the  
murine BMP-9 sequence (SEQ ID NO:1), nucleotides #32-#33 are  
inserted to facilitate efficient restriction digestion of two  
adjacent restriction endonuclease sites (EcoO109 I and Xba I),  
25 nucleotides #34-#60 correspond to nucleotides #1515-#1541 of  
the murine BMP-9 sequence (SEQ ID NO:1) except that nucleotide  
#58 of synthetic oligonucleotide #5 is a G rather than the A  
which appears at position #1539 of SEQ ID NO:1 (This nucleotide  
conversion results in the creation of an Apa I restriction

endonuclease recognition sequence, without altering the amino acid sequence it is intended to encode, to facilitate further manipulations of the murine/human hybrid expression plasmid. LINK-1 (the double stranded product of the annealing of 5 oligonucleotides #5 and #6) is subcloned into the plasmid vector pGEM-7zf(+) which has been digested with the restriction endonucleases Apa I and BamH I. This results in a plasmid in which the sequences normally present between the Apa I and BamH I sites of the pGEM-7zf(+) plasmid polylinker are replaced with 10 the sequences of LINK-1 described above. The resulting plasmid clone is designated pBMP-9link.

pBMP-9link is digested with the restriction endonucleases BamH I and Xba I resulting in the removal nucleotides #1-#34 of LINK-1 (refer to the numbering of oligo #5). Clone ML14a, 15 which contains an insert comprising the sequence set forth in SEQ ID NO:1, is also digested with the restriction endonucleases BamH I and Xba I resulting in the removal of sequences comprising nucleotides #1-#1515 of SEQUENCE ID NO:1 (murine BMP-9). This BamH I/Xba I fragment of mouse BMP-9 is 20 isolated from the remainder of the ML14a plasmid clone and subcloned into the BamH I/Xba I sites generated by the removal of the synthetic linker sequences described above. The resulting clone is designated p302.

The p302 clone is digested with the restriction endonuclease EcoO109 I resulting in the excision of nucleotides corresponding to nucleotides #621-#1515 of the murine BMP-9  
?

sequence (SEQ ID NO:1) and nucleotides #35-#59 of LINK-1 (refer to numbering of oligonucleotide #5). It should be noted that the Apa I restriction site created in LINK-1 by the A to G conversion described above is a subset of the recognition sequence of EcoO109 I, therefore digestion of p302 with EcoO109 I cleaves at the Apa I site as well as the naturally occurring murine EcoO109 I (location #619-#625 of SEQ ID NO:1) resulting in the excision of a 920 bp EcoO109 I/EcoO109 I (Apa I) fragment comprising the sequences described above. This 920 EcoO109 I/EcoO109 I (Apa I) fragment is isolated from the remainder of the p302 plasmid clone and subcloned into clone pBMP-9link which has been similarly digested with EcoO109 I. It should be noted that the nucleotides GG (#32-#33 of oligonucleotide #5) originally designed to facilitate a more complete digestion of the two adjacent restriction sites EcoO109 I and Xba I of LINK-1, which is now a part of pBMP-9link (described above), results in the creation of Dcm methylation recognition sequence. The restriction nuclease EcoO109 I is sensitive to Dcm methylation and therefore cleavage of this sequence (nucleotides #25-#31 of oligonucleotide #5/LINK-1) by the restriction endonuclease EcoO109 I is prevented at this site. Therefore the plasmid clone pBMP-9link is cleaved at the Apa I site but not at the EcoO109 I site upon digestion with the restriction endonuclease EcoO109 I as described above, preventing the intended removal of the sequences between the EcoO109 I and Xba I site of LINK-1

(#32-#55 defined by the numbering of oligonucleotide #5). This results in the insertion of the 920 bp Eco0109 I/Apa I fragment at the Eco0109 I (Apa I) site of pBMP-9link. The resulting clone is designated p318.

5       Clone p318 is digested with the restriction endonucleases Sal I and Apa I, resulting in the excision of sequences comprising nucleotides #6-#56 of LINK-1 (refer to oligo #5 for location), nucleotides #621-#1515 of murine BMP-9 (SEQ ID NO:1), and nucleotides #35-#60 of LINK-1 (refer to oligo #5 for  
10      location). The resulting 972 bp Sal I/Apa I fragment described above is isolated from the remainder of the p318 plasmid clone and will be utilized in subsequent manipulations.

15      The clone phBMP9mex-1 (described above), which contains DNA sequences which encode the entire mature region and portions of the propeptide of the human BMP-9 protein, is digested with the restriction endonucleases Apa I and EcoR I. This results in the excision of a 374 bp fragment comprising nucleotides #105-#470 of the human BMP-9 sequence (SEQ ID NO:8) and the additional nucleotides of oligonucleotide primers #3  
20      and #4 which contain the recognition sequences for the restriction endonucleases Apa I and EcoR I. This 374 bp Apa I/EcoR I fragment is combined with the 972 bp Sal I/Apa I fragment from p138 (isolation described above) and ligated to the mammalian cell expression plasmid pED6 (a derivative of pEMC2 $\beta$ 1) which has been digested with Sal I and EcoR I. The  
25      resulting clone is designated p324.

The clone ML14a (murine BMP-9) is digested with EcoO109 I and Xba I to generate a fragment comprising nucleotides #621-#1515 of SEQ ID NO:1.

5 The following oligonucleotides are synthesized on an automated DNA synthesizer and combined such that their complimentary sequences can base pair (anneal) with each other to generate a double stranded synthetic DNA linker designated LINK-2:

#7 TCGACCACCATGTCCCCCTGG

10 #8 GCCCCAGGGGACATGGTGG

This double stranded synthetic DNA linker (LINK-2) anneals in such a way that it generates single stranded ends which are compatible to DNA fragments digested with Sal I (one end) or EcoO109 I (the other end) as indicated below:

15 #7 TCGACCACCATGTCCCCCTGG  
GGTGGTACAGGGGACCCCG #8

This LINK-2 synthetic DNA linker is ligated to the 895 bp EcoO109 I/Xba I fragment comprising nucleotides #621-#1515 of murine BMP-9 (SEQ ID NO:1) described above. This results in a 20 915 bp Sal I/Xba I fragment.

The clone p324 is digested with Sal I/Xba I to remove sequences comprising nucleotides #6-#56 of LINK-1 (refer to oligo #5 for location) and nucleotides #621-#1515 of murine BMP-9 (SEQ ID NO:1). The sequences comprising nucleotides #35-25 #60 of LINK-1 (refer to oligo #5 for location) and the sequences comprising the 374 bp Apa I/EcoR I fragment (human BMP-9 sequences) derived from phBMP9mex-1 remain attached to

th pED6 backbone. The 915 bp Sal I/Xba I fragment comprising LINK-2 sequences and nucleotides #621-#1515 of murine BMP-9 (SEQ ID NO:1) is ligated into the p324 clone from which the Sal I to Xba I sequences described above have been removed.

5       The resulting plasmid is designated BMP9fusion and comprises LINK-2, nucleotides #621-#1551 of murine BMP-9 (SEQ ID NO:1), nucleotides #35-#59 of LINK-1 (refer to the numbering of oligonucleotide #5), and the 374 bp Apa I/EcoR I fragment (human BMP-9) derived from clone pBMP9mex-1 (described above)  
10      inserted between the Sal I and EcoR I sites of the mammalian cell expression vector pED6.

15      BMP9 fusion is transfected into CHO cells using standard techniques known to those having ordinary skill in the art to create stable cell lines capable of expressing human BMP-9 protein. The cell lines are cultured under suitable culture conditions and the BMP-9 protein is isolated and purified from the culture medium.

#### EXAMPLE V

##### 20      Biological Activity of Expressed BMP-9

25      To measure the biological activity of the expressed BMP-9 proteins obtained in Example IV above, the proteins are recovered from the cell culture and purified by isolating the BMP-9 proteins from other proteinaceous materials with which they are co-produced as well as from other contaminants. The purified protein may be assayed in accordance with the rat bone

formation assay described in Example III.

Purification is carried out using standard techniques known to those skilled in the art. It is contemplated, as with other BMP proteins, that purification may include the use of  
5 Heparin sepharose.

Protein analysis is conducted using standard techniques such as SDS-PAGE acrylamide [U.K. Laemmli, Nature **227**:680 (1970)] stained with silver [R.R. Oakley, et al. Anal. Biochem. **105**:361 (1980)] and by immunoblot [H. Towbin, et al. Proc. Natl. Acad. Sci. USA **76**:4350 (1979)]  
10

The foregoing descriptions detail presently preferred embodiments of the present invention. Numerous modifications and variations in practice thereof are expected to occur to those skilled in the art upon consideration of these descriptions.  
15 Those modifications and variations are believed to be encompassed within the claims appended hereto.

## (1) GENERAL INFORMATION:

- (i) APPLICANT: Wozney, John M.  
Celeste, Anthony
- (ii) TITLE OF INVENTION: BMP-9 COMPOSITIONS
- (iii) NUMBER OF SEQUENCES: 9
- (iv) CORRESPONDENCE ADDRESS:
  - (A) ADDRESSEE: Genetics Institute, Inc.
  - (B) STREET: Legal Affairs - 87 Cambridge Park Drive
  - (C) CITY: Cambridge
  - (D) STATE: MA
  - (E) COUNTRY: US
  - (F) ZIP: 02140
- (v) COMPUTER READABLE FORM:
  - (A) MEDIUM TYPE: Floppy disk
  - (B) COMPUTER: IBM PC compatible
  - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
  - (D) SOFTWARE: PatentIn Release #1.0, Version #1.25
- (vi) CURRENT APPLICATION DATA:
  - (A) APPLICATION NUMBER: US
  - (B) FILING DATE:
  - (C) CLASSIFICATION:
- (viii) ATTORNEY/AGENT INFORMATION:
  - (A) NAME: Kapinos, Ellen J.
  - (B) REGISTRATION NUMBER: 32,245
  - (C) REFERENCE/DOCKET NUMBER: GI 5186A
- (ix) TELECOMMUNICATION INFORMATION:
  - (A) TELEPHONE: (617) 876-1170
  - (B) TELEFAX: (617) 876-5851

## (2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 2447 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: double
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: cDNA to mRNA
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
  - (A) ORGANISM: Mus musculus
  - (B) STRAIN: C57B46xCBA
  - (F) TISSUE TYPE: liver

(vii) IMMEDIATE SOURCE:  
 (A) LIBRARY: Mouse liver cDNA  
 (B) CLONE: ML14A

(viii) POSITION IN GENOME:  
 (C) UNITS: bp

(ix) FEATURE:  
 (A) NAME/KEY: mat peptide  
 (B) LOCATION: 1564..1893

(ix) FEATURE:  
 (A) NAME/KEY: CDS  
 (B) LOCATION: 610..1896

(ix) FEATURE:  
 (A) NAME/KEY: mRNA  
 (B) LOCATION: 1..2447

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

CATTAATAAA TATTAAGTAT TGGAATTAGT GAAATTGGAG TTCCCTGTGG AAGGAAGTGG	60
GCAAGTGAGC TTTTAGTTT GTGTCGGAAG CCTGTAATT A CGGCTCCAGC TCATAGTGG	120
ATGGCTATAAC TTAGATTTAT GGATAGTTGG GTAGTAGGTG TAAATGTATG TGGTAAAAGG	180
CCTAGGAGAT TTGTTGATCC AATAAAATATG ATTAGGGAAA CAATTATTAG GGTTCATGTT	240
CGTCCTTTG GTGTGTGGAT TAGCATTATT TGTTTGATAA TAAGTTAAC TAGTCAGTGT	300
TGGAAAGAAT GGAGACGGTT GTTGATTAGG CGTTTGAGG ATGGGAATAG GATTGAAGGA	360
AATATAATGA TGGCTACAAC GATTGGAAT CCTATTATTG TTGGGTAAT GAATGAGGCA	420
AATAGATTTT CGTTCATTTT AATTCTCAAG GGGTTTTAC TTTTATGTTT GTTAGTGATA	480
TTGGTGAGTA GGCCAAGGGT TAATAGTGT A TTGAATTAT AGTCAAATCA TATTACTAGA	540
CCTGATGTTA GAAGGAGGGC TGAAAAGGCT CCTTCCCTCC CAGGACAAAA CCCGAGCAGG	600
GCCACCCGG ATG TCC CCT GGG GCC TTC CGG GTG GCC CTG CTC CCG CTG Met Ser Pro Gly Ala Phe Arg Val Ala Leu Leu Pro Leu	648
-318            -315            -310	
TTC CTG CTG GTC TGT GTC ACA CAG CAG AAG CCG CTG CAG AAC TGG GAA Phe Leu Leu Val Cys Val Thr Gln Gln Lys Pro Leu Gln Asn Trp Glu	696
-305            -300            -295            -290	
CAA GCA TCC CCT GGG GAA AAT GCC CAC AGC TCC CTG GGA TTG TCT GGA Gln Ala Ser Pro Gly Glu Asn Ala His Ser Ser Leu Gly Leu Ser Gly	744
-285            -280            -275	
GCT GGA GAG GAG GGT GTC TTT GAC CTG CAG ATG TTC CTG GAG AAC ATG Ala Gly Glu Gly Val Phe Asp Leu Gln Met Phe Leu Glu Asn Met	792
-270            -265            -260	
AAG GTG GAT TTC CTA CGC AGC CTT AAC CTC AGC GGC ATT CCC TCC CAG Lys Val Asp Phe Leu Arg Ser Leu Asn Leu Ser Gly Ile Pro Ser Gln	840

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 151 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

\* Thr Arg Glu Cys Ser Arg Ser Cys Pro Arg Thr Ala Pro Gln Arg  
-41 -40 -35 -30

Gln Val Arg Ala Val Thr Arg Arg Thr Arg Met Ala His Val Ala Ala  
-25 -20 -15 -10

Gly Ser Thr Leu Ala Arg Arg Lys Arg Ser Ala Gly Ala Gly Ser His  
-5 1 5

Cys Gln Lys Thr Ser Leu Arg Val Asn Phe Glu Asp Ile Gly Trp Asp  
10 15 20

Ser Trp Ile Ile Ala Pro Lys Glu Tyr Glu Ala Tyr Glu Cys Lys Gly  
25 30 35

Gly Cys Phe Phe Pro Leu Ala Asp Asp Val Thr Pro Thr Lys His Ala  
40 45 50 55

Ile Val Gln Thr Leu Val His Leu Lys Phe Pro Thr Lys Val Gly Lys  
60 65 70

Ala Cys Cys Val Pro Thr Lys Leu Ser Pro Ile Ser Val Leu Tyr Lys  
75 80 85

Asp Asp Met Gly Val Pro Thr Leu Lys Tyr His Tyr Glu Gly Met Ser  
90 95 100

Val Ala Glu Cys Gly Cys Arg  
105 110

(ix) FEATURE:  
 (A) NAME/KEY: exon  
 (B) LOCATION: 1..470

(ix) FEATURE:  
 (A) NAME/KEY: CDS  
 (B) LOCATION: 1..456

(ix) FEATURE:  
 (A) NAME/KEY: mat\_peptide  
 (B) LOCATION: 124..453

(ix) FEATURE:  
 (A) NAME/KEY: mRNA  
 (B) LOCATION: 1..470

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

TGA ACA AGA GAG TGC TCA AGA AGC TGT CCA AGG ACG GCT CCA CAG AGG * Thr Arg Glu Cys Ser Arg Ser Cys Pro Arg Thr Ala Pro Gln Arg -41 -40	48
CAG GTG AGA GCA GTC ACG AGG AGG ACA CGG ATG GCG CAC GTG GCT GCG Gln Val Arg Ala Val Thr Arg Arg Thr Arg Met Ala His Val Ala Ala -25	96
GGG TCG ACT TTA GCC AGG CGG AAA AGG AGC GCC GGG GCT GGC AGC CAC Gly Ser Thr Leu Ala Arg Arg Lys Arg Ser Ala Gly Ala Gly Ser His -5 1 5	144
TGT CAA AAG ACC TCC CTG CCG GTA AAC TTC GAG GAC ATC GGC TGG GAC Cys Gln Lys Thr Ser Leu Arg Val Asn Phe Glu Asp Ile Gly Trp Asp 10 15 20	192
AGC TGG ATC ATT GCA CCC AAG GAG TAT GAA GCC TAC GAG TGT AAG GGC Ser Trp Ile Ile Ala Pro Lys Glu Tyr Glu Ala Tyr Glu Cys Lys Gly 25 30 35	240
GGC TGC TTC TTC CCC TTG GCT GAC GAT GTG ACG CCG ACG AAA CAC GCT Gly Cys Phe Phe Pro Leu Ala Asp Asp Val Thr Pro Thr Lys His Ala 40 45 50 55	288
ATC GTG CAG ACC CTG GTG CAT CTC AAG TTC CCC ACA AAG GTG GGC AAG Ile Val Gln Thr Leu Val His Leu Lys Phe Pro Thr Lys Val Gly Lys 60 65 70	336
GCC TGC TGT GTG CCC ACC AAA CTG AGC CCC ATC TCC GTC CTC TAC AAG Ala Cys Cys Val Pro Thr Lys Leu Ser Pro Ile Ser Val Leu Tyr Lys 75 80 85	384
GAT GAC ATG GGG GTG CCC ACC CTC AAG TAC CAT TAC GAG GGC ATG AGC Asp Asp Met Gly Val Pro Thr Leu Lys Tyr His Tyr Glu Gly Met Ser 90 95 100	432
GTG GCA GAG TGT GGG TGC AGG TAGTATCTGC CTGCGGG Val Ala Glu Cys Gly Cys Arg 105 110	470

CATGGGCAGC TCGAG

(2) INFORMATION FOR SEQ ID NO:6:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 34 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: double  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA to mRNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

CTGCAGGCGA GCCTGAATT CTCGAGCCAT CATG

34

(2) INFORMATION FOR SEQ ID NO:7:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 68 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: double  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA to mRNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

CGAGGTTAAA AAACGTCTAG GCCCCCCGAA CCACGGGGAC GTGGTTTTCC TTTGAAAAAC

60

ACGATTGC

68

(2) INFORMATION FOR SEQ ID NO:8:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 470 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: double  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(v) FRAGMENT TYPE: C-terminal

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens  
(H) CELL LINE: W138 (genomic DNA)

(vii) IMMEDIATE SOURCE:

- (A) LIBRARY: human genomic library  
(B) CLONE: lambda lll-1

(viii) POSITION IN GENOME:

- (C) UNITS: bp

Arg Ile Asn Ile Tyr Glu Val Met Lys Pr Pro Ala Glu Val Val Pro  
 -115 -110 -105  
 Gly His Leu Ile Thr Arg Leu Leu Asp Thr Arg Leu Val His His Asn  
 -100 -95 -90 -85  
 Val Thr Arg Trp Glu Thr Phe Asp Val Ser Pro Ala Val Leu Arg Trp  
 -80 -75 -70  
 Thr Arg Glu Lys Gln Pro Asn Tyr Gly Leu Ala Ile Glu Val Thr His  
 -65 -60 -55  
 Leu His Gln Thr Arg Thr His Gln Gly Gln His Val Arg Ile Ser Arg  
 -50 -45 -40  
 Ser Leu Pro Gln Gly Ser Gly Asn Trp Ala Gln Leu Arg Pro Leu Leu  
 -35 -30 -25  
 Val Thr Phe Gly His Asp Gly Arg Gly His Ala Leu Thr Arg Arg Arg  
 -20 -15 -10 -5  
 Arg Ala Lys Arg Ser Pro Lys His His Ser Gln Arg Ala Arg Lys Lys  
 1 5 10  
 Asn Lys Asn Cys Arg Arg His Ser Leu Tyr Val Asp Phe Ser Asp Val  
 15 20 25  
 Gly Trp Asn Asp Trp Ile Val Ala Pro Pro Gly Tyr Gln Ala Phe Tyr  
 30 35 40  
 Cys His Gly Asp Cys Pro Phe Pro Leu Ala Asp His Leu Asn Ser Thr  
 45 50 55 60  
 Asn His Ala Ile Val Gln Thr Leu Val Asn Ser Val Asn Ser Ser Ile  
 65 70 75  
 Pro Lys Ala Cys Cys Val Pro Thr Glu Leu Ser Ala Ile Ser Met Leu  
 80 85 90  
 Tyr Leu Asp Glu Tyr Asp Lys Val Val Leu Lys Asn Tyr Gln Glu Met  
 95 100 105  
 Val Val Glu Gly Cys Gly Cys Arg  
 110 115

## (2) INFORMATION FOR SEQ ID NO:5:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 15 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: double
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA to mRNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

TGT GGG TGC CGC TGAGATCAGG CAGTCCTTGA GGATAGACAG ATATACACAC	1666
Cys Gly Cys Arg	
115	
 CACACACACA CACCACATAC ACCACACACA CACGTTCCCA TCCACTCACC CACACACTAC	1726
ACAGACTGCT TCCTTATAGC TGGACTTTA TTTAAAAAAA AAAAAAAA AATGGAAAAA	1786
ATCCCCTAAC ATTCACTTG ACCTTATTTA TGACTTTACG TGCAAATGTT TTGACCATAT	1846
TGATCATATA TTTTGACAAA ATATATTAT AACTACGTAT TAAAAGAAAA AAATAAAATG	1906
AGTCATTATT TTAAAAAAA AAAAAAAACT CTAGAGTCGA CGGAATTC	1954

**(2) INFORMATION FOR SEQ ID NO:4:**

- (i) SEQUENCE CHARACTERISTICS:

  - (A) LENGTH: 408 amino acids
  - (B) TYPE: amino acid
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Met Ile Pro Gly Asn Arg Met Leu Met Val Val Leu Leu Cys Gln Val  
 -292 -290 -285 -280  
 Leu Leu Gly Gly Ala Ser His Ala Ser Leu Ile Pro Glu Thr Gly Lys  
 -275 -270 -265  
 Lys Lys Val Ala Glu Ile Gln Gly His Ala Gly Gly Arg Arg Ser Gly  
 -260 -255 -250 -245  
 Gln Ser His Glu Leu Leu Arg Asp Phe Glu Ala Thr Leu Leu Gln Met  
 -240 -235 -230  
 Phe Gly Leu Arg Arg Arg Pro Gln Pro Ser Lys Ser Ala Val Ile Pro  
 -225 -220 -215  
 Asp Tyr Met Arg Asp Leu Tyr Arg Leu Gln Ser Gly Glu Glu Glu  
 -210 -205 -200  
 Glu Gln Ile His Ser Thr Gly Leu Glu Tyr Pro Glu Arg Pro Ala Ser  
 -195 -190 -185  
 Arg Ala Asn Thr Val Arg Ser Phe His His Glu Glu His Leu Glu Asn  
 -180 -175 -170 -165  
 Ile Pro Gly Thr Ser Glu Asn Ser Ala Phe Arg Phe Leu Phe Asn Leu  
 -160 -155 -150  
 Ser Ser Ile Pro Glu Asn Glu Val Ile Ser Ser Ala Glu Leu Arg Leu  
 -145 -140 -135  
 Phe Arg Glu Gln Val Asp Gln Gly Pro Asp Trp Glu Arg Gly Phe His  
 -130 -125 -120

GTG GAC CAG GGC CCT GAT TGG GAA AGG GGC TTC CAC CGT ATA AAC ATT Val Asp Gln Gly Pro Asp Trp Glu Arg Gly Ph His Arg Ile Asn Ile -125 -120 -115	942
TAT GAG GTT ATG AAG CCC CCA GCA GAA GTG GTG CCT GGG CAC CTC ATC Tyr Glu Val Met Lys Pro Pro Ala Glu Val Val Pro Gly His Leu Ile -110 -105 -100	990
ACA CGA CTA CTG GAC ACG AGA CTG GTC CAC CAC AAT GTG ACA CGG TGG Thr Arg Leu Leu Asp Thr Arg Leu Val His His Asn Val Thr Arg Trp -95 -90 -85	1038
GAA ACT TTT GAT GTG AGC CCT GCG GTC CTT CGC TGG ACC CGG GAG AAG Glu Thr Phe Asp Val Ser Pro Ala Val Leu Arg Trp Thr Arg Glu Lys -80 -75 -70 -65	1086
CAG CCA AAC TAT GGG CTA GCC ATT GAG GTG ACT CAC CTC CAT CAG ACT Gln Pro Asn Tyr Gly Leu Ala Ile Glu Val Thr His Leu His Gln Thr -60 -55 -50	1134
CGG ACC CAC CAG GGC CAG CAT GTC AGG ATT AGC CGA TCG TTA CCT CAA Arg Thr His Gln Gly Gln His Val Arg Ile Ser Arg Ser Leu Pro Gln -45 -40 -35	1182
GGG AGT GGG AAT TGG GCC CAG CTC CGG CCT CTC CGT GTC ACC TTT GGC Gly Ser Gly Asn Trp Ala Gln Leu Arg Pro Leu Leu Val Thr Phe Gly -30 -25 -20	1230
CAT GAT GGC CGG GGC CAT GCC TTG ACC CGA CGC CGG AGG GCC AAG CGT His Asp Gly Arg Gly His Ala Leu Thr Arg Arg Arg Arg Ala Lys Arg -15 -10 -5	1278
AGC CCT AAG CAT CAC TCA CAG CGG GCC AGG AAG AAG AAT AAG AAC TGC Ser Pro Lys His His Ser Gln Arg Ala Arg Lys Lys Asn Lys Asn Cys 1 5 10 15	1326
CGG CGC CAC TCG CTC TAT GTG GAC TTC AGC GAT GTG GGC TGG AAT GAC Arg Arg His Ser Leu Tyr Val Asp Phe Ser Asp Val Gly Trp Asn Asp 20 25 30	1374
TGG ATT GTG GCC CCA CCA GGC TAC CAG GCC TTC TAC TGC CAT GGG GAC Trp Ile Val Ala Pro Pro Gly Tyr Gln Ala Phe Tyr Cys His Gly Asp 35 40 45	1422
TGC CCC TTT CCA CTG GCT GAC CAC CTC AAC TCA ACC AAC CAT GCC ATT Cys Pro Phe Pro Leu Ala Asp His Leu Asn Ser Thr Asn His Ala Ile 50 55 60	1470
G TG CAG ACC CTG GTC AAT TCT GTC AAT TCC AGT ATC CCC AAA GCC TGT Val Gln Thr Leu Val Asn Ser Val Asn Ser Ser Ile Pro Lys Ala Cys 65 70 75 80	1518
TGT GTG CCC ACT GAA CTG AGT GCC ATC TCC ATG CTG TAC CTG GAT GAG Cys Val Pro Thr Glu Leu Ser Ala Ile Ser Met Leu Tyr Leu Asp Glu 85 90 95	1566
TAT GAT AAG GTG GTA CTG AAA AAT TAT CAG GAG ATG GTA GTA GAG GGA Tyr Asp Lys Val Val Leu Lys Asn Tyr Gln Glu Met Val Val Glu Gly 100 105 110	1614

(B) LOCATION: 9..1934

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

CTCTAGAGGG CAGAGGAGGA GGGAGGGAGG GAAGGAGCGC GGAGCCCGGC CCGGAAGCTA	60
GGTGAGTGTG GCATCCGAGC TGAGGGACGC GAGCCTGAGA CGCCGCTGCT GCTCCGGCTG	120
AGTATCTAGC TTGTCTCCCC GATGGGATTC CCGTCCAAGC TATCTCGAGC CTGCAGCGCC	180
ACAGTCCCCG GCCCTCGCCC AGGTCACTG CAACCGTTCA GAGGTCCCCA GGAGCTGCTG	240
CTGGCGAGCC CGCTACTGCA GGGACCTATG GAGCCATTCC GTAGTGCCAT CCCGAGCAAC	300
GCACTGCTGC AGCTTCCCTG AGCCTTCCA GCAAGTTGT TCAAGATTGG CTGTCAAGAA	360
TCATGGACTG TTATTATATG CCTTGTCCCC TGTCAAGACA CC ATG ATT CCT GGT Met Ile Pro Gly	414
-292 -290	
AAC CGA ATG CTG ATG GTC GTT TTA TGA CAA GTC CTG CTA GGA GGC Asn Arg Met Leu Met Val Val Leu Leu Cys Gln Val Leu Leu Gly Gly	462
-285 -280 -275	
GCG AGC CAT GCT AGT TTG ATA CCT GAG ACG GGG AAG AAA AAA GTC GCC Ala Ser His Ala Ser Leu Ile Pro Glu Thr Gly Lys Lys Val Ala	510
-270 -265 -260	
GAG ATT CAG GGC CAC GCG GGA GGA CGC CGC TCA GGG CAG AGC CAT GAG Glu Ile Gln Gly His Ala Gly Gly Arg Arg Ser Gly Gln Ser His Glu	558
-255 -250 -245	
CTC CTG CGG GAC TTC GAG GCG ACA CTT CTG CAG ATG TTT GGG CTG CGC Leu Leu Arg Asp Phe Ala Thr Leu Leu Gln Met Phe Gly Leu Arg	606
-240 -235 -230 -225	
CGC CGC CCG CAG CCT AGC AAG AGT GCC GTC ATT CCG GAC TAC ATG CGG Arg Arg Pro Gln Pro Ser Lys Ser Ala Val Ile Pro Asp Tyr Met Arg	654
-220 -215 -210	
GAT CTT TAC CGG CTT CAG TCT GGG GAG GAG GAA GAG CAG ATC CAC Asp Leu Tyr Arg Leu Gln Ser Gly Glu Glu Glu Glu Gln Ile His	702
-205 -200 -195	
AGC ACT GGT CTT GAG TAT CCT GAG CGC CCG GCC AGC CGG GCC AAC ACC Ser Thr Gly Leu Glu Tyr Pro Glu Arg Pro Ala Ser Arg Ala Asn Thr	750
-190 -185 -180	
GTG AGG AGC TTC CAC CAC GAA GAA CAT CTG GAG AAC ATC CCA GGG ACC Val Arg Ser Phe His His Glu Glu His Leu Glu Asn Ile Pro Gly Thr	798
-175 -170 -165	
AGT GAA AAC TCT GCT TTT CGT TTC CTC TTT AAC CTC AGC AGC ATC CCT Ser Glu Asn Ser Ala Phe Arg Phe Leu Phe Asn Leu Ser Ser Ile Pro	846
-160 -155 -150 -145	
GAG AAC GAG GTG ATC TCC TCT GCA GAG CTT CGG CTC TTC CGG GAG CAG Glu Asn Glu Val Ile Ser Ser Ala Glu Leu Arg Leu Phe Arg Glu Gln	894
-140 -135 -130	

	40		
-10		-5	1
Gly Ala Ser Ser His Cys Gln Lys Thr Ser Leu Arg Val Asn Phe Glu			
5	10	15	
Asp Ile Gly Trp Asp Ser Trp Ile Ile Ala Pro Lys Glu Tyr Asp Ala			
20	25	30	
Tyr Glu Cys Lys Gly Gly Cys Phe Phe Pro Leu Ala Asp Asp Val Thr			
35	40	45	50
Pro Thr Lys His Ala Ile Val Gln Thr Leu Val His Leu Glu Phe Pro			
55	60	65	
Thr Lys Val Gly Lys Ala Cys Cys Val Pro Thr Lys Leu Ser Pro Ile			
70	75	80	
Ser Ile Leu Tyr Lys Asp Asp Met Gly Val Pro Thr Leu Lys Tyr His			
85	90	95	
Tyr Glu Gly Met Ser Val Ala Glu Cys Gly Cys Arg			
100	105	110	

## (2) INFORMATION FOR SEQ ID NO:3:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 1954 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: double
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: cDNA to mRNA
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
  - (A) ORGANISM: Homo sapiens
  - (G) CELL TYPE: Osteosarcoma Cell Line
  - (H) CELL LINE: U-2OS
- (vii) IMMEDIATE SOURCE:
  - (A) LIBRARY: U2OS cDNA in Lambda gt10
  - (B) CLONE: Lambda U2OS-3
- (viii) POSITION IN GENOME:
  - (C) UNITS: bp
- (ix) FEATURE:
  - (A) NAME/KEY: CDS
  - (B) LOCATION: 403..1629
- (ix) FEATURE:
  - (A) NAME/KEY: mat\_peptide
  - (B) LOCATION: 1279..1626
- (ix) FEATURE:
  - (A) NAME/KEY: mRNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Met Ser Pr Gly Ala Phe Arg Val Ala Leu Leu Pro Leu Ph Leu Leu  
-318 -315 -310 -305

Val Cys Val Thr Gln Gln Lys Pro Leu Gln Asn Trp Glu Gln Ala Ser  
-300 -295 -290

Pro Gly Glu Asn Ala His Ser Ser Leu Gly Leu Ser Gly Ala Gly Glu  
-285 -280 -275

Glu Gly Val Phe Asp Leu Gln Met Phe Leu Glu Asn Met Lys Val Asp  
-270 -265 -260 -255

Phe Leu Arg Ser Leu Asn Leu Ser Gly Ile Pro Ser Gln Asp Lys Thr  
-250 -245 -240

Arg Ala Glu Pro Pro Gln Tyr Met Ile Asp Leu Tyr Asn Arg Tyr Thr  
-235 -230 -225

Thr Asp Lys Ser Ser Thr Pro Ala Ser Asn Ile Val Arg Ser Phe Ser  
-220 -215 -210

Val Glu Asp Ala Ile Ser Thr Ala Ala Thr Glu Asp Phe Pro Phe Gln  
-205 -200 -195

Lys His Ile Leu Ile Phe Asn Ile Ser Ile Pro Arg His Glu Gln Ile  
-190 -185 -180 -175

Thr Arg Ala Glu Leu Arg Leu Tyr Val Ser Cys Gln Asn Asp Val Asp  
-170 -165 -160

Ser Thr His Gly Leu Glu Gly Ser Met Val Val Tyr Asp Val Leu Glu  
-155 -150 -145

Asp Ser Glu Thr Trp Asp Gln Ala Thr Gly Thr Lys Thr Phe Leu Val  
-140 -135 -130

Ser Gln Asp Ile Arg Asp Glu Gly Trp Glu Thr Leu Glu Val Ser Ser  
-125 -120 -115

Ala Val Lys Arg Trp Val Arg Ala Asp Ser Thr Thr Asn Lys Asn Lys  
-110 -105 -100 -95

Leu Glu Val Thr Val Gln Ser His Arg Glu Ser Cys Asp Thr Leu Asp  
-90 -85 -80

Ile Ser Val Pro Pro Gly Ser Lys Asn Leu Pro Phe Phe Val Val Phe  
-75 -70 -65

Ser Asn Asp Arg Ser Asn Gly Thr Lys Glu Thr Arg Leu Glu Leu Lys  
-60 -55 -50

Glu Met Ile Gly His Glu Gln Glu Thr Met Leu Val Lys Thr Ala Lys  
-45 -40 -35

Asn Ala Tyr Gln Val Ala Gly Glu Ser Gln Glu Glu Gly Leu Asp  
-30 -25 -20 -15

Gly Tyr Thr Ala Val Gly Pro Leu Leu Ala Arg Arg Lys Arg Ser Thr

-15	-10	-5	
AGG AGC ACC GGA GCC AGC AGC CAC TGC CAG AAG ACT TCT CTC AGG GTG Arg Ser Thr Gly Ala Ser Ser His Cys Gln Lys Thr Ser Leu Arg Val 1 5 10 15			1608
AAC TTT GAG GAC ATC GGC TGG GAC AGC TGG ATC ATT GCA CCC AAG GAA Asn Phe Glu Asp Ile Gly Trp Asp Ser Trp Ile Ile Ala Pro Lys Glu 20 25 30			1656
TAT GAC GCC TAT GAG TGT AAA GGG GGT TGC TTC CCA TTG GCT GAT Tyr Asp Ala Tyr Glu Cys Lys Gly Cys Phe Pro Leu Ala Asp 35 40 45			1704
GAC GTG ACA CCC ACC AAA CAT GCC ATC GTG CAG ACC CTG GTG CAT CTC Asp Val Thr Pro Thr Lys His Ala Ile Val Gln Thr Leu Val His Leu 50 55 60			1752
GAG TTC CCC ACA AAG GTG GGC AAA GCC TGC TGC GTT CCC ACC AAA CTG Glu Phe Pro Thr Lys Val Gly Lys Ala Cys Cys Val Pro Thr Lys Leu 65 70 75			1800
AGT CCC ATC TCC ATC CTC TAC AAG GAT GAC ATG GGG GTG CCA ACC CTC Ser Pro Ile Ser Ile Leu Tyr Lys Asp Asp Met Gly Val Pro Thr Leu 80 85 90 95			1848
AAG TAC CAC TAT GAG GGG ATG AGT GTG GCT GAG TGT GGG TGT AGG TAGTCCCTGC Lys Tyr His Tyr Glu Gly Met Ser Val Ala Glu Cys Gly Cys Arg 100 105 110			1903
AGCCACCCAG GGTGGGGATA CAGGACATGG AAGAGGTTCT GGTACGGTCC TGCACTCCTCC			1963
TGGCGATGGT ATGCCCTAAGT TGATCAGAAA CCATCCTTGA GAAGAAAAAGG AGTTAGTTGC			2023
CCTTCTTGTG TCTGGTGGGT CCCTCTGCTG AAGTGACAAT GACTGGGTA TGCGGGCCTG			2083
TGGGCAGAGC AGGAGACCCT GGAAGGGTTA GTGGGTAGAA AGATGTAAA AAGGAAGCTG			2143
TGGGTAGATG ACCTGCACTC CAGTGATTAG AAGTCCAGCC TTACCTGTGA GAGAGCTCCT			2203
GGCATCTAAG AGAACTCTGC TTCCCTCATCA TCCCCACCGA CTTGTTCTTC CTTGGGAGTG			2263
TGTCCCTCAGG GAGAACAGCA TTGCTGTTCC TGTGCCTCAA GCTCCCAGCT GACTCTCCTG			2323
TGGCTCATAG GACTGAATGG GGTGAGGAAG AGCCTGATGC CCTCTGGCAA TCAGAGCCCG			2383
AAGGACTTCA AAACATCTGG ACAACTCTCA TTGACTGATG CTCCAACATA ATTTTTAAAAA			2443
AGAG			2447

## (2) INFORMATION FOR SEQ ID NO:2:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 428 amino acids
  - (B) TYPE: amino acid
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein

-255	-250	-245	
GAC AAA ACC AGA GCG GAG CCA CCC CAG TAC ATG ATC GAC TTG TAC AAC Asp Lys Thr Arg Ala Glu Pr Pr Gln Tyr Met Il Asp Leu Tyr Asn			888
-240	-235	-230	
AGA TAC ACA ACG GAC AAA TCG TCT ACG CCT GCC TCC AAC ATC GTG CGG Arg Tyr Thr Thr Asp Lys Ser Ser Thr Pro Ala Ser Asn Ile Val Arg			936
-225	-220	-215	-210
AGC TTC AGC GTG GAA GAT GCT ATA TCG ACA GCT GCC ACG GAG GAC TTC Ser Phe Ser Val Glu Asp Ala Ile Ser Thr Ala Ala Thr Glu Asp Phe			984
-205	-200	-195	
CCC TTT CAG AAG CAC ATC CTG ATC TTC AAC ATC TCC ATC CCG AGG CAC Pro Phe Gln Lys His Ile Leu Ile Phe Asn Ile Ser Ile Pro Arg His			1032
-190	-185	-180	
GAG CAG ATC ACC AGG GCT GAG CTC CGA CTC TAT GTC TCC TGC CAA AAT Glu Gln Ile Thr Arg Ala Glu Leu Arg Leu Tyr Val Ser Cys Gln Asn			1080
-175	-170	-165	
GAT GTG GAC TCC ACT CAT GGG CTG GAA GGA AGC ATG GTC GTT TAT GAT Asp Val Asp Ser Thr His Gly Leu Glu Gly Ser Met Val Val Tyr Asp			1128
-160	-155	-150	
GTT CTG GAG GAC AGT GAG ACT TGG GAC CAG GCC ACG GGG ACC AAG ACC Val Leu Glu Asp Ser Glu Thr Trp Asp Gln Ala Thr Gly Thr Lys Thr			1176
-145	-140	-135	-130
TTC TTG GTA TCC CAG GAC ATT CGG GAC GAA GGA TGG GAG ACT TTA GAA Phe Leu Val Ser Gln Asp Ile Arg Asp Glu Gly Trp Glu Thr Leu Glu			1224
-125	-120	-115	
GTA TCG AGT GCC GTG AAG CGG TGG GTC AGG GCA GAC TCC ACA ACA AAC Val Ser Ser Ala Val Lys Arg Trp Val Arg Ala Asp Ser Thr Thr Asn			1272
-110	-105	-100	
AAA AAT AAG CTC GAG GTG ACA GTG CAG AGC CAC AGG GAG AGC TGT GAC Lys Asn Lys Leu Glu Val Thr Val Gln Ser His Arg Glu Ser Cys Asp			1320
-95	-90	-85	
ACA CTG GAC ATC AGT GTC CCT CCA GGT TCC AAA AAC CTG CCC TTC TTT Thr Leu Asp Ile Ser Val Pro Pro Gly Ser Lys Asn Leu Pro Phe Phe			1368
-80	-75	-70	
GTT GTC TTC TCC AAT GAC CGC AGC AAT GGG ACC AAG GAG ACC AGC AGA CTG Val Val Phe Ser Asn Asp Arg Ser Asn Gly Thr Lys Glu Thr Arg Leu			1416
-65	-60	-55	-50
GAG CTG AAG GAG ATG ATC GGC CAT GAG CAG GAG ACC ATG CTT GTG AAG Glu Leu Lys Glu Met Ile Gly His Glu Gln Glu Thr Met Leu Val Lys			1464
-45	-40	-35	
ACA GCC AAA AAT GCT TAC CAG GTG GCA GGT GAG AGC CAA GAG GAG GAG Thr Ala Lys Asn Ala Tyr Gln Val Ala Gly Glu Ser Gln Glu Glu Glu			1512
-30	-25	-20	
GGT CTA GAT GGA TAC ACA GCT GTG GGA CCA CTT TTA GCT AGA AGG AAG Gly Leu Asp Gly Tyr Thr Ala Val Gly Pro Leu Leu Ala Arg Arg Lys			1560

**What is claimed is:**

1. A BMP-9 polypeptide comprising the amino acid sequence from amino acid #8 - 110 as set forth in FIG. 3 (SEQ ID NO: 9).
2. A BMP-9 polypeptide comprising the amino acid sequence from amino acid #1 - 110 as set forth in FIG. 3 (SEQ ID NO: 9).
3. A BMP-9 polypeptide of claim 1 wherein said polypeptide is a dimer wherein each subunit comprises at least the amino acid sequence from amino acid #8 - 110 of FIG. 3 (SEQ ID NO: 9).
4. A BMP-9 polypeptide of claim 2 wherein said polypeptide is a dimer wherein each subunit comprises at least the amino acid sequence from amino acid #1-110 of FIG. 3. (SEQ ID NO: 9).
5. A purified BMP-9 protein produced by the steps of
  - (a) culturing a cell transformed with a cDNA comprising the nucleotide sequence from nucleotide #124 to #453 as shown in FIG. 3 (SEQ ID NO: 8); and
  - (b) recovering and purifying from said culture medium a protein comprising the amino acid sequence from amino acid #1 to amino acid #110 as shown in FIG. 3 (SEQ ID NO: 9).
6. A purified BMP-9 protein produced by the steps of
  - (a) culturing a cell transformed with a cDNA comprising

the nucleotide sequence from nucleotide #124 to #453 as shown in FIG. 3 (SEQ ID NO: 8); and

(b) recovering from said culture medium a protein comprising an amino acid sequence from amino acid #8 to amino acid #110 as shown in Figure 3 (SEQ ID NO: 9).

7. A BMP-9 protein characterized by the ability to induce the formation of cartilage and/or bone.

8. A DNA sequence encoding a BMP-9 protein.

9. The DNA sequence of claim 8 wherein said DNA comprises

(a) nucleotide 124 to 453 (SEQ ID NO: 8); and

(b) sequences which hybridize thereto under stringent hybridization conditions and exhibit the ability to form cartilage and/or bone.

10. The DNA sequence of claim 8 wherein said DNA comprises

(a) nucleotide 145 to 453 (SEQ ID NO: 8); and

(b) sequences which hybridize thereto under stringent hybridization conditions and exhibit the ability to form cartilage and/or bone.

11. A host cell transformed with a DNA sequence encoding BMP-8.

12. A method for producing a purified BMP-9 protein said method comprising the steps of

(a) culturing a cell transformed with a cDNA comprising the nucleotide sequence encoding a BMP-9 protein; and

(b) recovering and purifying said BMP-9 protein from the culture medium.

13. A pharmaceutical composition comprising an effective amount of a BMP-9 protein in admixture with a pharmaceutically acceptable vehicle.

14. A composition of claim 13 further comprising a matrix for supporting said composition and providing a surface for bone and/or cartilage growth.

15. The composition of claim 14 wherein said matrix comprises a material selected from the group consisting of hydroxyapatite, collagen, polylactic acid and tricalcium phosphate.

16. A method for inducing bone and/or cartilage formation in a patient in need of same comprising administering to said patient an effective amount of the composition of claim 13.

17. A pharmaceutical composition for wound healing and tissue repair said composition comprising an effective amount of the

47

protein of a BMP-9 protein in a pharmaceutically acceptable vehicle.

18. A method for treating wounds and/or tissue repair in a patient in need of same comprising administering to said patient an effective amount of the composition of claim 17.

118

**Figure 1A**

10            20            30            40            50            60            70  
 CATTAATAAA TATTAAGTAT TGGAATTAGT GAAATTGGAG TTCTTGTTG AAGGAAGTGG GCAAGTGAGC  
 80            90            100          110          120          130          140  
 TTTTTAGTTT GTGTCGGAAG CCTGTAATTA CGGCTCCAGC TCATAGTGGGA ATGGCTATAC TTAGATTAT  
 150          160          170          180          190          200          210  
 GGATAGTTGG GTAGTAGGTG TAAATGTATG TGGTAAAAGG CCTAGGAGAT TTGTTGATCC AATAAATATG  
 220          230          240          250          260          270          280  
 ATTAGGGAAA CAATTATTAGG GTTTCATGTT CGTCCTTTTG GTGTGTGGGAT TAGCATTATT TGTTTGATAA  
 290          300          310          320          330          340          350  
 TAAGTTAAC TAGTCAGTGT TGGAAAGAAT GGAGACGGTT GTTGATTAGG CGTTTGAGG ATGGGAATAG  
 360          370          380          390          400          410          420  
 GATTGAAGGA AATATAATGA TGGCTACAAAC GATTGGGAAT CCTATTATTG TTGGGGTAAT GAATGAGGCA  
 430          440          450          460          470          480          490  
 AATAGATTT CGTTCATTTT AATTCTCAAG GGGTTTTAC TTTTATGTTT GTTAGTGTATA TTGGTGAGTA  
 500          510          520          530          540          550          560  
 GGCCAAGGGT TAATAGTGTAA ATTGAATTAT AGTGAATCA TATTACTAGA CCTGATGTTA GAAGGAGGGC  
 570          580          590          600          609          618  
 >  
 TGAAAAGGCT CCTTCCCTCC CAGGACAAAAA CCGGAGCAGG GCCACCCGG ATG TCC CCT GGG  
 M S P G  
 627          636          645          654          663          672  
GCC TTC CGG GTG GCC CTG CTC CCG CTG TTC CTG CTG GTC TGT GTC ACA CAG CAG  
 A F R V A L L P L F L V C V T Q Q  
 681          690          699          708          717          726  
AAG CCG CTG CAG AAC TGG GAA CAA GCA TCC CCT GGG GAA AAT GCC CAC AGC TCC  
 K P L Q N W E Q A S P G E N A H S S  
 735          744          753          762          771          780  
CTG GGA TTG TCT GGA GCT GGA GAG GAG GGT GTC TTT GAC CTG CAG ATG TTC CTG  
 L G L S G A G E E G V F D L Q M F L  
 789          798          807          816          825          834  
GAG AAC ATG AAG CTG GAT TTC CTA CGC AGC CTT AAC CTC AGC GGC ATT CCC TCC  
 E N M K V D F L R S L N L S G I P S

*2/8*

Figure 1B

843	852	861	870	879	888
CAG GAC AAA ACC AGA GCG GAG CCA CCC CAG TAC ATG ATC GAC TTG TAC AAC AGA					
Q D K T R A E P P Q Y M I D L Y N R					
897	906	915	924	933	942
TAC ACA ACG GAC AAA TCG TCT ACG CCT GCC TCC AAC ATC GTG CGG AGC TTC AGC					
Y T T D K S S T P A S N I V R S F S					
951	960	969	978	987	996
GTG GAA GAT GCT ATA TCG ACA GCT GCC ACG GAG GAC TTC CCC TTT CAG AAG CAC					
V E D A I S T A A T B D F P F Q K H					
1005	1014	1023	1032	1041	1050
ATC CTG ATC TTC AAC ATC TCC ATC CCG AGG CAC GAG CAG ATC ACC AGG GCT GAG					
I L I F N I S I P R H E Q I T R A E					
1059	1068	1077	1086	1095	1104
CTC CGA CTC TAT GTC TCC TGC CAA AAT GAT GTG GAC TCC ACT CAT GGG CTG GAA					
L R L Y V S C Q N D V D S T H G L E					
1113	1122	1131	1140	1149	1158
GGA AGC ATG GTC GTT TAT GAT GTT CTG GAG GAC AGT GAG ACT TGG GAC CAG GCC					
G S M V V Y D V L E D S E T W D Q A					
1167	1176	1185	1194	1203	1212
ACG GGG ACC AAG ACC TTC TTG GTA TCC CAG GAC ATT CGG GAC GAA GGA TGG GAG					
T G T K T F L V S Q D I R D E G W E					
1221	1230	1239	1248	1257	1266
ACT TTA GAA GTA TCG AGT GCC GTG AAG CGG TGG GTC AGG GCA GAC TCC ACA ACA					
T L E V S S A V K R W V R A D S T T					
1275	1284	1293	1302	1311	1320
AAC AAA AAT AAG CTC GAG GTG ACA GTG CAG AGC CAC AGG GAG AGC TGT GAC ACA					
N K N K L E V T V Q S H R E S C D T					
1329	1338	1347	1356	1365	1374
CTG GAC ATC AGT GTC CCT CCA GGT TCC AAA AAC CTG CCC TTC TTT GTT GTC TTC					
L D I S V P P G S K N L P F F V V F					

3/8

Figure 1C

1383	1392	1401	1410	1419	1428
TCC AAT GAC CGC AGC AAT	GGG ACC AAG GAG ACC AGA	CTG GAG CTG AAG GAG ATG			
S N D R S N G T K E T R L E L K E M					
1437	1446	1455	1464	1473	1482
ATC GGC CAT GAG CAG GAG ACC ATG CTT GTG AAG ACA	GCC AAA AAT GCT TAC CAG				
I G H E Q E T M L V K T A K N A Y Q					
1491	1500	1509	1518	1527	1536
GTG GCA GGT GAG AGC CAA GAG GAG GAG GGT CTA GAT GGA TAC ACA	GCT GTG GGA				
V A G E S Q E E E G L D G Y T A V G					
1545	1554	1563	1572	1581	1590
CCA CCTT TTA GCT AGA AGG AAG AGG AGC ACC GGA GCC AGC AGC CAC TGC CAG AAG					
P L L A R R K R S T G A S S H C Q K					
1599	1608	1617 (319)	1626	1635 (326)	1644
ACT TCT CTC AGG GTG AAC TTT GAG GAC ATC GGC TGG GAC AGC TGG ATC ATT GCA					
T S L R V N F E D I G W D S W I I A					
1653	1662	1671	1680	1689	1698
CCC AAG GAA TAT GAC GCC TAT GAG TGT AAA GGG GGT TGC TTC TTC CCA TTG GCT					
P K E Y D A Y E C K G G C F F P L A					
1707	1716	1725	1734	1743	1752
GAT GAC GTG ACA CCC ACC AAA CAT GCC ATC GTG CAG ACC CTG GTG CAT CTC GAG					
D D V T P T K H A I V Q T L V H L E					
1761	1770	1779	1788	1797	1806
TTC CCC ACA AAG GTG GGC AAA GCC TGC TGC GTT CCC ACC AAA CTG AGT CCC ATC					
F P T K V G K A C C V P T K L S P I					
1815	1824	1833	1842	1851	1860
TCC ATC CTC TAC AAG GAT GAC ATG GGG GTG CCA ACC CTC AAG TAC CAC TAT GAG					
S I L Y K D D M G V P T L K Y H Y E					
1869	1878	1887	1903	1913	1923
GGG ATG AGT GTG GCT GAG TGT GGG TGT AGG > TAGTCCCTGC AGCCACCCAG GGTGGGGATA					
G M S V A E C G C R	(428)				

Figure 1D

1933	1943	1953	1963	1973	1983	1993
CAGGACATGG	AAGAGGTTCT	GGTACGGTCC	TGCATCCTCC	TGCGCATGGT	ATGCCTAAGT	TGATCAGAAA
2003	2013	2023	2033	2043	2053	2063
CCATCCTTGA	GAAGAAAAAGG	AGTTAGTTGC	CCTTCTTG TG	TCTGGTGGGT	CCCTCTGCTG	AAGTGACAAT
2073	2083	2093	2103	2113	2123	2133
GACTGGGGTA	TGCGGGCCTG	TGGGCAGAGC	AGGAGACCC	GGAAGGGTTA	GTGGGTAGAA	AGATGTCAAA
2143	2153	2163	2173	2183	2193	2203
AAGGAAGCTG	TGGGTAGATG	ACCTGCACTC	CAGTGATTAG	AAGTCCAGCC	TTACCTGTGA	GAGAGCTCCT
2213	2223	2233	2243	2253	2263	2273
GGCATCTAACG	AGAACTCTGC	TTCCTCATCA	TCCCCACCGA	CTTGTCTTC	CTTGGGAGTG	TGTCCCTCAGG
2283	2293	2303	2313	2323	2333	2343
GAGAACAGCA	TTGCTGTTCC	TGTGCCTCAA	GCTCCCAGCT	GACTCTCCTG	TGGCTCATAG	GACTGAATGG
2353	2363	2373	2383	2393	2403	2413
GGTGAGGAAG	AGCCTGATGC	CCTCTGGCAA	TCAGAGCCCG	AAGGACTTCA	AAACATCTGG	ACAACTCTCA
2423	2433	2443				
TTGACTGATG	CTCCAACATA	ATTTTTAAAA	AGAG			

*5/8*

Figure 2

Figure 2

```

      10          20          30          40          50          60          70
CTCTAGAGGG CAGAGGGAGGA GGGAGGGAGG GAAGGAGCGC GGAGCCCGGC CCGGAAGCTA GGTGAGTGTG

      80          90         100         110         120         130         140
GCATCCGAGC TGAGGGACGC GAGCCTGAGA CGCCGCTGCT GCTCCGGCTG AGTATCTAGC TTGTCTCCCC

      150         160         170         180         190         200         210
GATGGGATTC CCGTCCAAGC TATCTCGAGC CTGCAGCGCC ACAGTCCCCG GCCCTCGCCC AGGTTCACTG

      220         230         240         250         260         270         280
CAACCGTTCA GAGGTCCCCA GGAGCTGCTG CTGGCGAGCC CGCTACTGCA GGGACCTATG GAGCCATTCC

      290         300         310         320         330         340         350
GTAGTGCCAT CCCGAGCAAC GCACTGCTGC AGCTTCCCTG AGCCTTCCA GCAAGTTGT TCAAGATTGG

      360         370         380         390         400      (1)
CTGTCAAGAA TCATGGACTG TTATTATATG CCTTGTTTTC TGTCAAGACA CC ATG ATT CCT
                           MET Ile Pro

      417         432         447         462
GGT AAC CGA ATG CTG ATG GTC GTT TTA TTA TGC CAA GTC CTG CTA GGA GGC GCG
Gly Asn Arg MET Leu MET Val Val Leu Leu Cys Gln Val Leu Leu Gly Gly Ala

      477         492         507
AGC CAT GCT AGT TTG ATA CCT GAG ACG GGG AAG AAA AAA GTC GCC GAG ATT CAG
Ser His Ala Ser Leu Ile Pro Glu Thr Gly Lys Lys Val Ala Glu Ile Gln

      522         537         552         567
GGC CAC GCG GGA GGA CGC CGC TCA GGG CAG AGC CAT GAG CTC CTG CGG GAC TTC
Gly His Ala Gly Arg Arg Ser Gly Glu Ser His Glu Leu Arg Asp Phe

      582         597         612         627
GAG GCG ACA CTT CTG CAG ATG TTT GGG CTG CGC CGC CCG CAG CCT AGC AAG
Glu Ala Thr Leu Leu Gln MET Phe Gly Leu Arg Arg Pro Gln Pro Ser Lys

      642         657         672
AGT GCC GTC ATT CCG GAC TAC ATG CGG GAT CTT TAC CGG CTT CAG TCT GGG GAG
Ser Ala Val Ile Pro Asp Tyr MET Arg Asp Leu Tyr Arg Leu Gln Ser Gly Glu

      687
GAG GAG GAA GAG CAG ATC CAC AGC ACT GGT CTT GAG TAT CCT GAG CGC CCG GCC
Glu Glu Glu Gln Ile His Ser Thr Gly Leu Glu Tyr Pro Glu Arg Pro Ala

      747         762         777
AGC CGG GCC AAC ACC GTG AGG AGC TTC CAC CAC GAA GAA CAT CTG GAG AAC ATC
Ser Arg Ala Asn Thr Val Arg Ser Phe His His Glu Glu His Leu Glu Asn Ile

      792         807         822         837
CCA GGG ACC AGT GAA AAC TCT GCT TTT CGT TTC CTC TTT AAC CTC AGC AGC ATC
Pro Gly Thr Ser Glu Asn Ser Ala Phe Arg Phe Leu Phe Asn Leu Ser Ser Ile

```

6/8

Figure 2A

852                    867                    882                    897  
CCT GAG AAC GAG GTG ATC TCC TCT GCA GAG CTT CGG CTC TTC CGG GAG CAG GTG  
Pro Glu Asn Glu Val Ile Ser Ser Ala Glu Leu Arg Leu Phe Arg Glu Gln Val

912                    927                    942  
GAC CAG GGC CCT GAT TGG GAA AGG GGC TTC CAC CGT ATA AAC ATT TAT GAG GTT  
Asp Gln Gly Pro Asp Trp Glu Arg Gly Phe His Arg Ile Asn Ile Tyr Glu Val

957                    972                    987                    1002  
ATG AAG CCC CCA GCA GAA GTG GTG CCT GGG CAC CTC ATC ACA CGA CTA CTG GAC  
MET Lys Pro Pro Ala Glu Val Val Pro Gly His Leu Ile Thr Arg Leu Leu Asp

1017                    1032                    1047  
ACG AGA CTG GTC CAC CAC AAT GTG ACA CGG TGG GAA ACT TTT GAT GTG AGC CCF  
Thr Arg Leu Val His His Asn Val Thr Arg Trp Glu Thr Phe Asp Val Ser Pro

1062                    1077                    1092                    1107  
GCG GTC CCTT CGC TGG ACC CGG GAG CAG CCA AAC TAT GGG CTA GCC ATT GAG  
Ala Val Leu Arg Trp Thr Arg Glu Lys Gln Pro Asn Tyr Glu Ala Ile Glu

1122                    1137                    1152                    1167  
GTG ACT CAC CTC CAT CAG ACT CGG ACC CAC CAG GGC CAG CAT GTC AGG ATT AGC  
Val Thr His Leu His Gln Thr Arg Thr His Gln Gly Gln His Val Arg Ile Ser

1182                    1197                    1212  
CGA TCG TTA CCT CAA GGG AGT GGG AAT TGG GCC CAG CTC CGG CCC CTC CTG GTC  
Arg Ser Leu Pro Gln Gly Ser Gly Asn Trp Ala Gln Leu Arg Pro Leu Val

1227                    1242                    1257                    1272  
ACC TTT GGC CAT GAT GGC CGG GGC CAT GCC TTG ACC CGA CGC CGG AGG GCC AAG  
Thr Phe Gly His Asp Gly Arg His Ala Leu Thr Arg Arg Arg Ala Lys

1287                    1302                    1317  
CGT AGC CCT AAG CAT CAC TCA CAG CGG GCC AGG AAG AAT AAG AAC TGC CGG  
Arg Ser Pro Lys His His Ser Gln Arg Ala Arg Lys Lys Asn Lys Asn Cys Arg

1332(311)            1347                    1362                    1377  
CGC CAC TCG CTC TAT GTG GAC TTC AGC GAT GTG GGC TGG AAT GAC TGG ATT GTG  
Arg His Ser Leu Tyr Val Asp Phe Ser Asp Val Gly Trp Asn Asp Trp Ile Val

1392                    1407                    1422                    1437  
GCC CCA CCA GGC TAC CAG GCC TTC TAC TGC CAT GGG GAC TGC CCC TTT CCA CTG  
Ala Pro Pro Gly Tyr Gln Ala Phe Tyr Cys His Gly Asp Cys Pro Phe Pro Leu

1452                    1467                    1482  
GCT GAC CAC CTC AAC TCA ACC AAC CAT GCC ATT GTG CAG ACC CTG GTC AAT TCT  
Ala Asp His Leu Asn Ser Thr Asn His Ala Ile Val Gln Thr Leu Val Asn Ser

1497                    1512                    1527                    1542  
GTC AAT TCC AGT ATC CCC AAA GCC TGT TGT GTG CCC ACT GAA CTG AGT GCC ATC  
Val Asn Ser Ser Ile Pro Lys Ala Cys Cys Val Pro Thr Glu Leu Ser Ala Ile

*7/8*

## Figure 2B

1557                    1572                    1587  
 TCC ATG CTG TAC CTG GAT GAG TAT GAT AAG GTG GTA CTG AAA AAT TAT CAG GAG  
 Ser MET Leu Tyr Leu Asp Glu Tyr Asp Lys Val Val Leu Lys Asn Tyr Gln Glu  
 1602                    1617                    (408)                    1636                    1646                    1656  
 ATG GTA GTA GAG GGA TGT GGG TGC CGC TGAGATCAGG CAGTCCTTGA GGATAGACAG  
MET Val Val Glu Gly Cys Gly Cys Arg  
 1666                    1676                    1686                    1696                    1706                    1716                    1726  
 ATATACACAC CACACACACA CACCACATAC ACCACACACA CACGTTCCCA TCCACTCACC CACACACTAC  
 1736                    1746                    1756                    1766                    1776                    1786                    1796  
 ACAGACTGCT TCCTTATAGC TGGACTTTA TTTAAAAAAA AAAAAAAA AATGGAAAAA ATCCCTAAAC  
 1806                    1816                    1826                    1836                    1846                    1856                    1866  
 ATTACACCTTG ACCTTATTAA TGACTTTACG TGCAAATGTT TTGACCATAT TGATCATATA TTTTGACAAA  
 1876                    1886                    1896                    1906                    1916                    1926                    1936  
 ATATATTTAT AACTACGTAT TAAAAGAAAA AAATAAAATG AGTCATTATT TTAAAAAAA AAAAAAAACT  
 1946  
 CTAGAGTCGA CGGAATTC

8/8

**Figure 3**

TGA ACA AGA GAG TGC TCA AGA AGC TGT CCA AGG ACG GCT CCA CAG AGG * Thr Arg Glu Cys Ser Arg Ser Cys Pro Arg Thr Ala Pro Gln Arg -41 -40	-35	-30	48
CAG GTG AGA GCA GTC ACG AGG ACA CGG ATG GCG CAC GTG GCT GCG Gln Val Arg Ala Val Thr Arg Arg Thr Arg Met Ala His Val Ala Ala -25	-20	-15	96
GGG TCG ACT TTA GCC AGG CGG AAA AGG AGC GCC GGG GCT GGC AGC CAC Gly Ser Thr Leu Ala Arg Arg Lys Arg Ser Ala Gly Ala Gly Ser His -5	1	5	144
TGT CAA AAG ACC TCC CTG CGG GTA AAC TTC GAG GAC ATC GGC TGG GAC Cys Gln Lys Thr Ser Leu Arg Val Asn Phe Glu Asp Ile Gly Trp Asp 10	15	20	192
AGC TGG ATC ATT GCA CCC AAG GAG TAT GAA GCC TAC GAG TGT AAG GGC Ser Trp Ile Ile Ala Pro Lys Glu Tyr Glu Ala Tyr Glu Cys Lys Gly 25	30	35	240
GGC TGC TTC TTC CCC TTG GCT GAC GAT GTG ACG CCG ACG AAA CAC GCT Gly Cys Phe Phe Pro Leu Ala Asp Asp Val Thr Pro Thr Lys His Ala 40	45	50	288
ATC GTG CAG ACC CTG GTG CAT CTC AAG TTC CCC ACA AAG GTG GGC AAG Ile Val Gln Thr Leu Val His Leu Lys Phe Pro Thr Lys Val Gly Lys 60	65	70	336
GCC TGC TGT GTG CCC ACC AAA CTG AGC CCC ATC TCC GTC CTC TAC AAG Ala Cys Cys Val Pro Thr Lys Leu Ser Pro Ile Ser Val Leu Tyr Lys 75	80	85	384
GAT GAC ATG GGG GTG CCC ACC CTC AAG TAC CAT TAC GAG GGC ATG AGC Asp Asp Met Gly Val Pro Thr Leu Lys Tyr His Tyr Glu Gly Met Ser 90	95	100	432
GTG GCA GAG TGT GGG TGC AGG TAGTATCTGC CTGCGGG Val Ala Glu Cys Gly Cys Arg 105	110		470

## INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 92/05374

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all)<sup>6</sup>

According to International Patent Classification (IPC) or to both National Classification and IPC  
 Int.Cl. 5 C12N15/12; C12P21/02; A61K37/02

## II. FIELDS SEARCHED

Minimum Documentation Searched<sup>7</sup>

Classification System	Classification Symbols		
Int.Cl. 5	C07K ;	C12N ;	A61K

Documentation Searched other than Minimum Documentation  
 to the Extent that such Documents are Included in the Fields Searched<sup>8</sup>

III. DOCUMENTS CONSIDERED TO BE RELEVANT<sup>9</sup>

Category <sup>10</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>
A	WO,A,9 011 366 (GENETICS INSTITUTE, INC.) 4 October 1990 cited in the application see the whole document ---	1-18
A	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA vol. 87, no. 24, December 1990, WASHINGTON US pages 9843 - 9847 CELESTE, A.J. ET AL. 'Identification of transforming growth factor beta family members present in bone-inductive protein purified from bovine bone' see the whole document ---	1-18 -/-

\* Special categories of cited documents :<sup>10</sup>

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "Z" document member of the same patent family

## IV. CERTIFICATION

Date of the Actual Completion of the International Search  05 OCTOBER 1992	Date of Mailing of this International Search Report  19.10.92
--	---

International Searching Authority  
EUROPEAN PATENT OFFICE

Signature of Authorized Officer  
ANDRES S.M.

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
P,A	WO,A,9 118 098 (GENETICS INSTITUTE, INC.) 28 November 1991 cited in the application see the whole document -----	1-18

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US92/05374

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although claims 16, 18 are directed to a method of treatment of the human/animal body the search has been carried out and based on the alleged affects of the compound/composition.
2.  Claims Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3.  Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1.  As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.  As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4.  No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

## Remark on Protest

- The additional search fees were accompanied by the applicant's protest.  
 No protest accompanied the payment of additional search fees.

**ANNEX TO THE INTERNATIONAL SEARCH REPORT  
ON INTERNATIONAL PATENT APPLICATION NO. US 9205374  
SA 61850**

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.  
The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information. 05/10/92

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO-A-9011366	04-10-90	US-A-	5106748	21-04-92
		AU-A-	5357790	22-10-90
		CA-A-	2030518	29-09-90
		EP-A-	0429570	05-06-91
		JP-T-	3505098	07-11-91
-----	-----	-----	-----	-----
WO-A-9118098	28-11-91	None	-----	-----
-----	-----	-----	-----	-----